

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number
WO 01/58889 A1

(51) International Patent Classification⁷: **C07D 311/20**,
C07H 17/06

TX 78741 (US). LIU, Shenquan; 302 West 38th Street,
No. 212, Austin, TX 78705 (US). ISRAEL, Karen; 8800
North IH 35, Apt. 2148, Austin, TX 78753 (US).

(21) International Application Number: PCT/US01/04168

(74) Agent: WEILER, James, F.; 1 Riverway, Suite 1560,
Houston, TX 77056 (US).

(22) International Filing Date: 9 February 2001 (09.02.2001)

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(26) Publication Language: English

(30) Priority Data:
09/502,592 11 February 2000 (11.02.2000) US

(71) Applicant: RESEARCH DEVELOPMENT FOUNDA-
TION [US/US]; 402 North Division Street, Carson City,
NV 89703 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors: SANDERS, Robert, G.; 2005 Barton Hills
Drive, Austin, TX 78720 (US). KLINE, Kimberly; 2505
McCallum, Austin, TX 78703 (US). HURLEY, Laurence;
5811 Mesa Drive, No. 1316, Austin, TX 78731 (US).
GARDNER, Robb; 11900 Stonehollow Drive, No. 1031,
Austin, TX 78758 (US). MENCHACA, Marla; 11304
Tanya Trail, Austin, TX 78726 (US). YU, Weiping; 13413
Equestrian Cove, Austin, TX 78727 (US). RAMANAN,
Puthucode, N.; 2301 South Lakeshore Boulevard, Austin,


Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 01/58889 A1

(54) Title: TOCOPHEROLS, TOCOTRIENOLS, OTHER CHROMAN AND SIDE CHAIN DERIVATIVES AND USES THEREOF



(57) Abstract: The present invention provides an antiproliferative compound having the structural formula (I) wherein X is oxygen, nitrogen or sulfur; Y is selected from the group consisting of oxygen, nitrogen and sulfur wherein when Y is oxygen or nitrogen, n is 1 and when Y is sulfur, n is 0. Also provided is a method for inducing apoptosis in a cell comprising administering a composition comprising a compound.

TOCOPHEROLS, TOCOTRIENOLS, OTHER CHROMAN AND SIDE CHAIN DERIVATIVES AND USES THEREOF

5

BACKGROUND OF THE INVENTION

Field of the Invention

10 The present invention relates generally to the fields of
organic chemistry and antiproliferative and pro-apoptotic
compounds. More specifically, the present invention relates to
chroman-based compounds and derivatives and analogs thereof,
and their uses as cell anti-proliferative, proapoptotic,
15 immunomodulating, and anti-viral agents.

Description of the Related Art

 The biology of cell proliferation and cell death
(apoptosis) is extremely complex, involving multiple intracellular
20 signaling pathways and multiple interacting gene products. Cancer
cells may exhibit multiple defects in normal regulatory controls of
cell proliferation which allow them to increase in number.
Furthermore, cancer cells exhibit defects in mechanisms that are
involved in eliminating abnormal cells by multi-step processes
25 referred to as programmed cell death or apoptosis. Thus,
combinations of unregulated cell proliferation and suppression of
death inducing signaling pathways give cancer cells both growth and
survival advantages.

Whether a cell increases in numbers or not depends on a balance of expression of negatively-acting and positively-acting growth regulatory gene products, and the presence or absence of functional cell death signaling pathways. Negative-acting growth regulatory genes contribute to blockage of cells in the cell cycle. Positive-acting growth regulatory genes stimulate cells to progress through the cell cycle. Genes involved in apoptosis can be either proapoptotic or antiapoptotic, and the dynamic balance between them determines whether a cell lives or dies.

Cancer cells, in order to survive and increase their numbers, undergo a series of mutational events over time that remove regulatory controls that give them the ability to grow unchecked and survive even in the presence of proapoptotic signals, and develop attributes that permit them to escape detection and removal by the immune response defense system. Cancers may cause death of individuals unless removed by surgery or effectively treated with drugs.

A wide variety of pathological cell proliferative conditions exist for which novel therapeutic strategies and agents are needed to provide therapeutic benefits. These pathological conditions may occur in almost all cell types capable of abnormal cell proliferation or abnormal responsiveness to cell death signals. Among the cell types that exhibit pathological or abnormal growth and death characteristics are (1) fibroblasts, (2) vascular endothelial cells, and (3) epithelial cells. Thus, novel methods are needed to treat local or disseminated pathological conditions in all or almost all organ and tissue systems of individuals.

Most cancers, whether they be male specific such as prostate or testicular, or female specific such as breast, ovarian or

cervical or whether they affect males and females equally such as liver, skin or lung, with time undergo increased genetic lesions and epigenetic events, and eventually become highly metastatic and difficult to treat. Surgical removal of localized cancers has proven
5 effective only when the cancer has not spread beyond the primary lesion. Once the cancer has spread to other tissues and organs, the surgical procedures must be supplemented with other more specific procedures to eradicate the diseased or malignant cells. Most of the commonly utilized supplementary procedures for treating diseased
10 or malignant cells such as chemotherapy or bioradiation are not localized to the tumor cells and, although they have a proportionally greater destructive effect on malignant cells, often affect normal cells to some extent.

Some derivatives of tocopherols, tocotrienols and
15 vitamin E have been used as proapoptotic and DNA synthesis inhibiting agents. Structurally, vitamin E is composed of a chromanol head and an alkyl side chain. There are eight major naturally occurring forms of vitamin E: alpha (α), beta (β), gamma (γ), and delta (δ) tocopherols and α , β , γ , and δ tocotrienols.
20 Tocopherols differ from tocotrienols in that they have a saturated phytyl side chain rather than an unsaturated isoprenyl side chain. The four forms of tocopherols and tocotrienols differ in the number of methyl groups on the chromanol head (α has three, β and γ have two and δ has one).


25 RRR- α -tocopheryl succinate is a derivative of RRR- α -tocopherol that has been structurally modified via an ester linkage to contain a succinyl moiety instead of a hydroxyl moiety at the 6-position of the chromanol head. This ester linked succinate moiety of RRR- α -tocopherol has been the most potent form of vitamin E

affecting the biological actions of triggering apoptosis and inhibiting DNA synthesis. This form of vitamin E induces tumor cells to undergo apoptosis, while having no apoptotic inducing effects on normal cells. The major advantage of this form of vitamin E as an anticancer agent is that many cancer cells either express low levels of esterases or do not express esterases that can cleave the succinate moiety, thereby converting the succinate form of RRR- α -tocopherol to the free RRR- α -tocopherol. RRR- α -tocopherol exhibits neither potent antiproliferative nor apoptotic triggering biological activity. However, the ester-linked vitamin E succinate is ineffective in vivo since natural esterases in the host cleave off the succinate moiety, rendering an ineffective anticancer agent, RRR- α -tocopherol.

The prior art is deficient in the lack of effective means of inhibiting undesirable or uncontrollable cell proliferation in a wide variety of pathophysiological conditions while having no to little effect on normal cells. The present invention fulfills this long-standing need and desire in the art.


SUMMARY OF THE INVENTION

In one embodiment of the present invention, there is provided a compound having a structural formula



wherein X is oxygen, nitrogen or sulfur; Y is selected from the group consisting of oxygen, nitrogen and sulfur wherein when Y is oxygen or nitrogen, n is 1 and when Y is sulfur, n is 0; R¹ is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxylic acid, carboxylate, carboxamide, ester, thioamide, thiolester, thiolacid, saccharide, alkoxy-linked saccharide, amine, sulfonate, sulfate, phosphate, alcohol, ether and nitrile; R² is selected from the group consisting of hydrogen, methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzyl ester, saccharide and amine; R³ is selected from the group consisting of hydrogen, methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide and amine; R⁴ is selected from the group consisting of methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide and amine; and R⁵ is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxyl, amide and ester; wherein when Y is nitrogen, said nitrogen is substituted with R⁶, wherein R⁶ is selected from the group consisting of hydrogen and methyl; wherein when X is oxygen, R² is methyl, R³ is methyl, R⁴ is methyl and R⁵ is phytyl, R¹ is not butyric acid.

In another embodiment of the present invention, there is provided a method for the treatment of a cell proliferative disease comprising administering to an animal a pharmacologically effective dose of a compound having a structural formula



wherein X is oxygen, nitrogen or sulfur; Y is selected from the group consisting of oxygen, nitrogen and sulfur wherein when Y is oxygen or nitrogen, n is 1 and when Y is sulfur, n is 0; R¹ is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, 5 carboxylic acid, carboxylate, carboxamide, ester, thioamide, thiolester, thiolacid, saccharide, alkoxy-linked saccharide, amine, sulfonate, sulfate, phosphate, alcohol, ether and nitrile; R² is selected from the group consisting of hydrogen, methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzyl 10 ester, saccharide and amine; R³ is selected from the group consisting of hydrogen, methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide and amine; R⁴ is selected from the group consisting of methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, 15 benzylester, saccharide and amine; and R⁵ is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxyl, amide and ester; wherein when Y is nitrogen, said nitrogen is substituted with R⁶, wherein R⁶ is selected from the group consisting of hydrogen and methyl..

20 In yet another embodiment of the present invention, there is provided a pharmaceutical composition comprising a compound disclosed herein and a pharmaceutically acceptable carrier.

25 In yet another embodiment of the present invention, there is provided a method of inducing apoptosis of a cell, comprising the step of contacting said cell with a pharmacologically effective dose of a compound of the present invention.

Other and further aspects, features, benefits, and advantages of the present invention will be apparent from the

following description of the presently preferred embodiments of the invention given for the purpose of disclosure.

5

BRIEF DESCRIPTION OF THE DRAWINGS

So that the matter in which the above-recited features, advantages and objects of the invention, as well as others which will become clear, are attained and can be understood in detail, more particular descriptions of the invention are briefly summarized. 10 above may be had by reference to certain embodiments thereof which are illustrated in the appended drawings. These drawings form a part of the specification. It is to be noted; however, that the appended drawings illustrate preferred embodiments of the 15 invention and therefore are not to be considered limiting in their scope.

Figure 1 shows general structure of tocopherol, tocotrienol and other chromanol-based compounds.

Figure 2 shows general tocopherol-based compounds 20 1-29 presently synthesized and tested.

Figures 3A, 3B and 3C shows general synthetic organic approaches for the chemical variation of chromanol compounds at position R¹.

Figure 4 shows general synthetic organic approaches 25 for the chemical variation of chromanol compounds at position R².

Figure 5 shows general synthetic organic approaches for the chemical variation of chromanol compounds at position R³ and R⁴.

Figure 6 shows general synthetic organic approaches for the chemical variation of chromanol compounds at position R⁵.

Figure 7 shows general synthetic organic approaches for the all-racemic 1-aza- α -tocopherol analogs. Figure 7A shows
5 the synthetic scheme for compounds 31-38 and Figure 7B shows the synthetic scheme for compounds 39-43.

Figure 8 shows the mean body weights of non-tumor Balb/c female mice at day 11 and day 23 of a maximum tolerated dose study.

10 Figure 9 shows the comparison of percent mean tumor weight following treatments in MDA MB-435 Human Breast Cancer Cells (Figure 9A), DU-145 Human Prostrate Cancer Cells (Figure 9B) and HT-29 Human Colon Cancer Cells (Figure 9C).

15

DETAILED DESCRIPTION OF THE INVENTION

The following definitions are given for the purpose of facilitating understanding of the inventions disclosed herein. Any
20 terms not specifically defined should be interpreted according to the common meaning of the term in the art.

As used herein, the term "individual" shall refer to animals and humans.

As used herein, the term "biologically inhibiting" or
25 "inhibition" of the growth of proliferating cells shall include partial or total growth inhibition and also is meant to include decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose of the composition of the present invention may be determined by assessing the effects of the test element on target

malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell culture or any other method known to those of ordinary skill in the art.

As used herein, the term "induction of programmed cell death or apoptosis" shall include partial or total cell death with cells exhibiting established morphological and biochemical apoptotic characteristics. The dose of the composition of the present invention that induces apoptosis may be determined by assessing the effects of the test element on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell culture or any other method known to those of ordinary skill in the art.

As used herein, the term "induction of cell cycle arrest" shall include growth arrest due to treated cells being blocked in GO/G1 or G2/M cell cycle phase. The dose of the composition of the present invention that induces cell cycle arrest may be determined by assessing the effects of the test element on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell culture or any other method known to those of ordinary skill in the art.

As used herein, the term "induction of cellular differentiation" shall include growth arrest due to treated cells being induced to undergo cellular differentiation, a stage in which cellular proliferation does not occur. The dose of the composition of the present invention that induces cellular differentiation may be determined by assessing the effects of the test element on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell culture or any other method known to those of ordinary skill in the art.

The present invention provides tocopherols, tocotrienols, and other chroman derivatives with or without derivatives of saturated phytyl or unsaturated isoprenyl side chains and analogs; e.g., azo- and thiol- analogs, thereof. Utilizing ethers
5 and several other chemical linkages to attach different moieties to tocopherol, tocotrienol and other chroman derivatives, novel anti-cancer compounds, for *in vivo* use, are produced. The general structures of the novel compounds of the present invention are shown in Figure 1, the preferred compounds are listed in Figure 2
10 and possible routes for their syntheses are provided in Figures 3-7. The novel features of these molecules include chemical functionalization of positions R¹ - R⁵ of the chroman structure, and chemical functionalization of the phytyl and isoprenyl side chains, particularly compounds based on tocopherols and tocotrienols
15 (Figure 1). Additionally, compounds with heteroatom substitutions (N or S) for the chroman ring oxygen are presented (Figure 7). Particularly preferred compounds include 2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy)acetic acid (1), 2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-
20 yloxy)propionic acid (2), 2,5,8-trimethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy)acetic acid (7), 2,7,8-trimethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy)acetic acid (8), 2,8-dimethyl-(2R-(4R,8R,12-trimethyltridecyl) chroman-6-yloxy)acetic acid (9), 2-(N,N-(carboxymethyl)-2(2,5,7,8-tetramethyl-(2R-
25 (4R,8R,12-trimethyltridecyl) chroman-6-yloxy) acetic acid (12), 2,5,7,8-tetramethyl-(2RS-(4RS,8RS,12-trimethyltridecyl)chroman-6-yloxy)acetic acid (15), 2,5,7,8-tetramethyl-2R-(2RS,6RS,10-trimethylundecyl)chroman-6-yloxy)acetic acid (17), 3-(2,5,7,8-tetramethyl-(2R-(4R,8,12-trimethyltridecyl)chroman-6-

yloxy)propyl-1-ammonium chloride (19), 2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-3-ene-6-yloxy) acetic acid (20), 2-(2,5,7,8-tetramethyl-(2R-(4R,8,12-trimethyltridecyl)chroman-6-yloxy)triethylammonium sulfate (21), 6-(2,5,7,8-tetramethyl-(2R-(4R,8,12-trimethyltridecyl)chroman)acetic acid (22), 2,5,7,8-tetramethyl-(2R-(heptadecyl)chroman-6-yloxy) acetic acid (25), 2,5,7,8-tetramethyl-2R-(4,8-dimethyl-1,3,7 E nonotrien)chroman-6-yloxy) acetic acid (26), E,Z,RS,RS-(phytyltrimethylbenzenethiol-6-yloxy)acetic acid (27), 1-aza- α -tocopherol-6-yloxyl-acetic acid (39), 1-aza- α -tocopherol-6-yloxyl-methyl acetate (40), 1-aza-N-methyl- α -tocopherol-6-yloxyl-methyl acetate (41), 1-aza-N-methyl- α -tocopherol-6-yloxyl-acetic acid (42), 6-(2,4-Dinitrophenylazo(2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-1,2,3,4-tetrahydroquinoline (43).

15 The pharmacodynamically designed compounds of the present invention have an improved therapeutic index and are potent inhibitors of cancer cell growth; i.e., they demonstrate high antitumor activity with minimal side effects. These compounds, which can not be readily degraded since there are no known
20 etherases in mammals, may be used in the treatment of cancers and disorders involving excess cell proliferation, as well as for cells that accumulate in numbers due to suppressed cell killing mechanisms, with minimal side effects. The compounds of the present invention inhibit cancer cell growth by induction of apoptosis and DNA
25 synthesis arrest. Induction of apoptosis by these compounds is mediated by activation of the TGF- β , stress kinase, and Fas/Fas ligand signaling pathways. Induction of apoptosis by other pathways, for example, ceramide production, are not excluded. These growth inhibitory properties allow these compounds to be

used in the treatment of proliferative diseases, including cancers of different cell types and lineages, non-neoplastic hyperproliferative diseases, and disorders with defects in apoptotic signaling pathways. Several of the compounds of the present invention are both strong
5 inducers of apoptosis and strong inhibitors of DNA synthesis arrest of tumor cells representing different cellular lineages.

The therapeutic use of the compounds of the present invention in treatment of cancers and other diseases and disorders involving excess cell proliferation or failure of cells to die is
10 illustrated. The novel derivatives (Tables 1 and 2) were shown at EC_{50} concentrations to induce apoptosis of human breast cancer cells (MDA MB 435, MDA MB 231, and MCF-7 breast cancer cells), human prostate cancer cells (PC-3, DU-145 and LnCaP), human ovarian tumor cells (C-170), human cervical tumor cells (ME-180),
15 human endometrial cells (RL-95-2), human lymphoid cells (myeloma, Raji, Ramos, Jurkat, and HL-60), colon cancer cells (HT-29 and DLD-1) and lung cancer cells (A-549). The novel derivatives were shown to not induce apoptosis of normal human mammary epithelial cells (HMECs) and immortalized but non-tumorigenic
20 MCF-10A mammary cells.

These novel compounds and methods of the present invention may be used to treat neoplastic diseases and non-neoplastic diseases. Representative examples of neoplastic diseases are ovarian cancer, cervical cancer, endometrial cancer, bladder
25 cancer, lung cancer, cervical cancer, breast cancer, prostate cancer, testicular cancer, gliomas, fibrosarcomas, retinoblastomas, melanomas, soft tissue sarcomas, osteosarcomas, colon cancer, carcinoma of the kidney, pancreatic cancer, basal cell carcinoma, and squamous cell carcinoma. Representative examples of non-

neoplastic diseases are selected from the group consisting of psoriasis, benign proliferative skin diseases, ichthyosis, papilloma, restinosis, scleroderma and hemangioma.

The compounds and methods of the present invention
5 may be used to treat non-neoplastic diseases that develop due to failure of selected cells to undergo normal programmed cell death or apoptosis. Representative examples of diseases and disorders that occur due to the failure of cells to die are autoimmune diseases. Autoimmune diseases are characterized by immune cell
10 destruction of self cells, tissues and organs. A representative group of autoimmune diseases includes autoimmune thyroiditis, multiple sclerosis, myasthenia gravis, systemic lupus erythematosus, dermatitis herpetiformis, celiac disease, and rheumatoid arthritis. This invention is not limited to autoimmunity, but includes all
15 disorders having an immune component, such as the inflammatory process involved in cardiovascular plaque formation, or ultra violet radiation induced skin damage.

The compounds and methods of the present invention may be used to treat disorders and diseases that develop due to
20 virus infections. Representative examples of diseases and disorders that occur due to virus infections are human immunodeficiency viruses (HIV). Since these compounds are working on intracellular signaling networks, they have the capacity to impact on any type of external cellular signal such as cytokines, viruses, bacteria, toxins,
25 heavy metals, etc.

The methods of the present invention may be used to treat any animal. Most preferably, the methods of the present invention are useful in humans.

Generally, to achieve pharmacologically efficacious cell killing and anti-proliferative effects, these compounds and analogs thereof may be administered in any therapeutically effective dose. Preferably, the structurally modified tocopherols and tocotrienols
5 and analogs are administered in a dose of from about 0.1 mg/kg to about 100 mg/kg. More preferably, the structurally modified tocopherols and tocotrienols and analogs are administered in a dose of from about 1 mg/kg to about 10 mg/kg.

Administration of the compositions of the present
10 invention may be by topical, intraocular, parenteral, oral, intranasal, intravenous, intramuscular, subcutaneous, or any other suitable means. The dosage administered is dependent upon the age, clinical stage and extent of the disease or genetic predisposition of the individual, location, weight, kind of concurrent treatment, if
15 any, and nature of the pathological or malignant condition. The effective delivery system useful in the method of the present invention may be employed in such forms as capsules, tablets, liquid solutions, suspensions, or elixirs, for oral administration, or sterile liquid forms such as solutions, suspensions or emulsions. For
20 topical use it may be employed in such forms as ointments, creams or sprays. Any inert carrier is preferably used in combination with suitable solubilizing agents, such as saline, or phosphate-buffered saline, or any such carrier in which the compounds used in the method, such as ethanol, acetone, or DMSO, of the present
25 invention have suitable solubility properties.

There are a wide variety of pathological cancerous and noncancerous cell proliferative conditions and cell accumulations due to absence of normal cellular death for which the compositions and methods of the present invention will provide therapeutic

benefits. These pathological conditions may occur in almost all cell types capable of abnormal cell proliferation or defective in programmed cell death mechanisms. Among the cell types which exhibit pathological or abnormal growth or abnormal death are (1) fibroblasts, (2) vascular endothelial cells and (3) epithelial cells. It can be seen from the above that the methods of the present invention is useful in treating local or disseminated pathological conditions in all or almost all organ and tissue systems of individuals.

10 It is specifically contemplated that pharmaceutical compositions may be prepared using the novel chroman-based compounds and derivatives and analogs thereof of the present invention. In such a case, the pharmaceutical composition comprises the novel compounds of the present invention and a
15 pharmaceutically acceptable carrier. A person having ordinary skill in this art would readily be able to determine, without undue experimentation, the appropriate dosages and routes of administration of the compounds and analogs of the present invention.

20 Thus the present invention is directed toward the design and effective use of novel agents that can specifically target cancer cells and either down-regulate growth stimulatory signals, up-regulate growth inhibitory signals, down-regulate survival signals and/or up-regulate death signals. More specifically, this invention
25 creates and characterizes novel agents that activate growth inhibitory factors, trigger death signaling pathways, and inhibit DNA synthesis.

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.

5

EXAMPLE 1

Synthetic Organic Methodology

The synthesis of a variety of tocopherol, tocotrienol, and other chroman derivatives with or without derivatives of saturated
10 phytyl or unsaturated isoprenyl side chains or analogs thereof is possible via structural modification of the chroman ring system (Figures 3-6) and heteroatom substitutions (N or S) for the chroman ring oxygen (Figure 7A and 7B). The structural variables R^1 , R^2 , R^3 , R^4 , R^5 , and X illustrate the groups on the chroman group that are
15 modified and Y represents either oxygen, or heteroatom substitutions (N or S) for the chroman ring oxygen. Using alkylation chemistry, a large number of compounds containing different R^1 groups can be synthesized, particularly when X is oxygen. After alkylation, further chemical modification of the R^1
20 groups permits the synthesis of a wide range of novel compounds. Bromination of the benzylic methyl groups of the chroman group provide intermediates that permit variation of the R^2 , R^3 and R^4 groups. Variation of group R^5 is also possible, particularly when starting from the commercially available 6-hydroxy-2,5,7,8-
25 tetramethylchroman-2-carboxylic acid. When a heteroatom substitution of nitrogen for the chroman ring oxygen occurs, than nitrogen may be substituted with R^6 which is hydrogen or methyl. Variation of X to groups other than oxygen, which is the identity of X in tocopherols and tocotrienols, can be accomplished using

palladium chemistry (for $X = CH_2$) and nucleophilic aromatic substitution (for $X = N$ or S). Other possible modifications to the chroman structure include unsaturation at the 3-4 positions and ring contraction to produce a five-membered furanyl ring.


5 Reagents employed were either commercially available or prepared according to a known procedure. Anhydrous CH_2Cl_2 and THF were obtained by distillation. All other solvents used were reagent. Anhydrous reaction conditions were maintained under a slightly positive argon atmosphere in oven-dried glassware. Silica
10 gel chromatography was performed using 230-400 mesh silica purchased from EM Science. Routine 1H - and ^{13}C -NMR spectra were obtained on a Varian Unity spectrometer at 300.132 MHz and 75.033 MHz frequencies, respectively. NMR spectra were referenced to TMS (0 ppm) or to the isotopic impurity peak of
15 $CDCl_3$ (7.26 and 77.0 ppm for 1H and ^{13}C , respectively). High resolution electron impact ionization mass spectroscopy was performed by the Mass Spectrometry Center at The University of Texas at Austin.

20

EXAMPLE 2

Synthesis and Characterization of Novel Tocopherol Compounds


2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy) acetic acid (1)



A solution of R,R,R- α -tocopherol (0.5 g, 1.16 mmol) in N,N-dimethylformamide (20 mL) was treated with methyl bromoacetate (3.4 g, 8.3 mmol) and an excess of powdered NaOH (1.2 g, 30 mmol). The resulting yellow slurry was stirred vigorously
5 for 24 h at room temperature. The reaction was acidified with 5 N HCl and extracted with diethyl ether (3 x 30 ml). The combined ether layers were washed with H₂O (3 x 30 ml) and brine (1 x 30 ml), and then dried with Na₂SO₄. The ether solution was concentrated to a yellow oil that was purified by silica gel
10 chromatography eluting with 19% (v/v) EtOAc and 2% acetic acid in hexanes. The resulting yellow liquid was dissolved in diethyl ether (30 ml), washed with H₂O (3 x 20 mL) and brine (1 x 20 mL), and then dried with Na₂SO₄. The resulting solution was concentrated to a light yellow oil and dried in vacuo for 48 h. This yielded 1 as a
15 waxy, off-white solid (0.50 g, 88%). ¹H-NMR (CDCl₃/TMS, ppm): 0.87 (m, 12H, 4a'-, 8a'-, 12a'-, 13'-CH₃), 1.0 - 1.6 (m, 24H, 4'-, 8'-, 12'-CH, 1'-, 2'-, 3'-, 5'-, 6'-, 7'-, 9'-, 10'-, 11'-CH₂, 2a-CH₃), 1.81 (m, 2H, 3-CH₂), 2.07, 2.14, 2.16 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.59 (t, J = 6.6 Hz, 2H, 4-CH₂), 4.34 (s, 2H, OCH₂); ¹³C-NMR (CDCl₃, ppm): 11.7,
20 11.8, 12.7 (5a-, 7a-, 8a-CH₃), 19.6, 19.7 (CH₃), 20.6, 21.0 (CH₂), 22.6, 22.7 (CH₃), 23.8 (2a-CH₃), 24.4, 24.8 (CH₂), 28.0 (CH), 31.2 (3-CH₂), 32.7, 32.8 (CH), 37.3, 37.4, 37.5, 39.4, 40.0 (CH₂), 69.2 (OCH₂), 75.0 (2-C), 117.8, 123.2, 125.4, 127.3 (aryl C), 147.0, 148.5 (aryl C-O), 173.7 (COOH); HRMS (CI, m/z): 489.394374 (M + H⁺, Calc. for C₃₁H₅₃O₄ 489.394386). All assignments were confirmed
25 using HMQC, DEPT-135, and ¹H-NOSEY.


2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl)
chroman-6-yloxy) propionic acid (2)

The compounds 2-6 are synthesized in a manner identical to the synthesis of 1 using the appropriate bromoalkanoic acids.




(89% yield). ¹H-NMR (CDCl₃/TMS, ppm): 0.87 (m, 12H, 4a'-, 8a'-, 12a'-, 13'-CH₃), 1.0 - 1.6 (m, 24H, 4'-, 8'-, 12'-CH, 1'-, 2'-, 3'-, 5'-, 6'-, 7'-, 9'-, 10'-, 11'-CH₂, 2a-CH₃), 1.81 (m, 2H, 3-CH₂), 2.09, 2.14, 2.19 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.59 (t, J = 6.6 Hz, 2H, 4-CH₂), 2.85 (t, J = 6.4 Hz, 2H, CH₂COOH), 3.96 (t, J = 6.4 Hz, 2H, OCH₂); ¹³C-NMR (CDCl₃, ppm): 11.7, 11.8, 12.7 (5a-, 7a-, 8a-CH₃), 19.6, 19.7 (CH₃), 20.6, 21.0 (CH₂), 22.6, 22.7 (CH₃), 23.8 (2a-CH₃), 24.4, 24.8 (CH₂), 28.0 (CH), 31.2 (3-CH₂), 32.7, 32.8 (CH), 35.1, 37.3, 37.4, 37.5, 39.4, 40.0 (CH₂), 67.5 (OCH₂), 74.8 (2-C), 117.5, 122.9, 125.8, 127.8 (aryl C), 147.6, 148.0 (aryl C-O), 177.1 (COOH); HRMS (CI, m/z): 503.408610 (M + H⁺, Calc. for C₃₂H₅₅O₄ 503.410036).

2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl)
chroman-6-yloxy) butyric acid (3)



(85% yield). ¹H-NMR (CDCl₃/TMS, ppm): 0.87 (m, 12H, 4a'-, 8a'-, 12a'-, 13'-CH₃), 1.0 - 1.6 (m, 26H, 4'-, 8'-, 12'-CH, 1'-, 2'-, 3'-, 5'-, 6'-, 7'-, 9'-, 10'-, 11'-CH₂, 2a-CH₃), 1.81 (m, 2H, 3-CH₂), 2.14, 2.17, 2.21 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.62 (t, J = 6.6 Hz, 2H, 4-CH₂), 2.72 (t, J = 7.2 Hz, 2H, CH₂COOH), 3.74 (t, J = 6.1 Hz, 2H, OCH₂); ¹³C-NMR (CDCl₃, ppm): 11.7, 11.8, 12.7 (5a-, 7a-, 8a-CH₃), 19.6, 19.7 (CH₃), 20.6, 21.0 (CH₂), 22.6, 22.7 (CH₃), 23.9 (2a-CH₃), 24.4, 24.8, 25.3 (CH₂), 28.0 (CH), 30.9, 31.2 (3-CH₂), 32.7, 32.8 (CH), 37.3, 37.4, 37.5, 39.4, 40.0 (CH₂), 71.3 (OCH₂), 74.8 (2-C), 117.5, 122.9, 125.7, 127.7 (aryl C), 147.8, 147.9 (aryl C-O), 178.9 (COOH); HRMS (CI, m/z): 516.424374 (M + H⁺, Calc. for C₃₃H₅₇O₄ 516.424386).


15 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)
chroman-6-yloxy) valeric acid (4)



20 (90% yield). ¹H-NMR (CDCl₃/TMS, ppm): 0.87 (m, 12H, 4a'-, 8a'-, 12a'-, 13'-CH₃), 1.0 - 1.6 (m, 28H, 4'-, 8'-, 12'-CH, 1'-, 2'-, 3'-, 5'-, 6'-, 7'-, 9'-, 10'-, 11'-CH₂, 2a-CH₃), 1.81 (m, 2H, 3-CH₂), 2.09, 2.14, 2.18 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.49 (t, J = 6.8 Hz, 2H, CH₂COOH), 2.59 (t, J = 6.6 Hz, 2H, 4-CH₂), 3.68 (t, J = 5.5 Hz, 2H, OCH₂); ¹³C-NMR (CDCl₃, ppm): 11.7, 11.8, 12.7 (5a-, 7a-, 8a-CH₃), 19.6, 19.7 (CH₃), 20.6, 21.0, 21.4 (CH₂), 22.6, 22.7 (CH₃), 23.8 (2a-

CH₃), 24.4, 24.8 (CH₂), 28.0 (CH), 30.0 (CH₂), 31.2 (3-CH₂), 32.7, 32.8 (CH), 35.8, 37.3, 37.4, 37.5, 39.4, 40.0 (CH₂), 72.2 (OCH₂), 74.9 (2-C), 117.8, 123.2, 125.4, 127.3 (aryl C), 147.6, 148.3 (aryl C-O), 178.7 (COOH); HRMS (CI, m/z): 530.433514 (M + H⁺, Calc. for C₃₄H₅₉O₄ 530.433516).

2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl) chroman-6-yloxy)hexanoic acid (5)




10

(77% yield). ¹H-NMR (CDCl₃/TMS, ppm): 0.87 (m, 12H, 4a'-, 8a'-, 12a'-, 13'-CH₃), 1.0 - 1.6 (m, 30H, 4'-, 8'-, 12'-CH, 1'-, 2'-, 3'-, 5'-, 6'-, 7'-, 9'-, 10'-, 11'-CH₂, 2a-CH₃), 1.81 (m, 2H, 3-CH₂), 2.08, 2.12, 2.16 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.32 (t, J = 6.5 Hz, 2H, CH₂COOH), 2.57 (t, J = 6.6 Hz, 2H, 4-CH₂), 3.64 (t, J = 5.5 Hz, 2H, OCH₂); ¹³C-NMR (CDCl₃, ppm): 11.8, 11.9, 12.7 (5a-, 7a-, 8a-CH₃), 19.6, 19.7 (CH₃), 20.6, 21.0 (CH₂), 22.6, 22.7 (CH₃), 23.8 (2a-CH₃), 24.4, 24.6, 24.8, 25.7 (CH₂), 28.0 (CH), 30.0 (CH₂), 31.3 (3-CH₂), 32.7, 32.8 (CH), 34.0, 37.3, 37.3, 37.4, 39.3, 40.0 (CH₂), 72.6 (OCH₂), 74.7 (2-C), 117.4, 122.7, 125.4, 127.8 (aryl C), 147.6, 148.2 (aryl C-O), 179.6 (COOH); HRMS (CI, m/z): 545.457026 (M + H⁺, Calc. for C₃₅H₆₁O₄ 545.456986).


25

2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)
chroman-6-yloxy)octanoic acid (6)



- 5 (91% yield). ¹H-NMR (CDCl₃/TMS, ppm): 0.87 (m, 12H, 4a'-, 8a'-, 12a'-, 13'-CH₃), 1.0 - 1.6 (m, 34H, 4'-, 8'-, 12'-CH, 1'-, 2'-, 3'-, 5'-, 6'-, 7'-, 9'-, 10'-, 11'-CH₂, 2a-CH₃), 1.81 (m, 2H, 3-CH₂), 2.08, 2.11, 2.16 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.36 (m, 2H, CH₂COOH), 2.58 (t, J = 6.6 Hz, 2H, 4-CH₂), 3.62 (t, J = 5.5 Hz, 2H, OCH₂); ¹³C-
- 10 NMR (CDCl₃, ppm): 11.7, 11.8, 12.7 (5a-, 7a-, 8a-CH₃), 19.6, 19.7 (CH₃), 20.6, 21.0 (CH₂), 22.6, 22.7 (CH₃), 23.8 (2a-CH₃), 24.4, 24.6, 24.8, 25.1, 25.7, 26.6 (CH₂), 28.0 (CH), 30.0 (CH₂), 31.3 (3-CH₂), 32.7, 32.8 (CH), 34.0, 37.3, 37.3, 37.4, 39.3, 40.0 (CH₂), 72.7 (OCH₂), 74.6 (2-C), 117.6, 122.8, 125.5, 127.6 (aryl C), 147.5,
- 15 148.3 (aryl C-O), 179.4 (COOH); HRMS (CI, m/z): 573.484396 (M + H⁺, Calc. for C₃₇H₆₅O₄ 573.488286).

2,5,8-trimethyl-(2R-(4R,8R,12-trimethyltridecyl)
chroman-6-yloxy)acetic acid (7)




20

A solution of R,R,R- α -tocopherol (75 mg, 0.18 mmol) in N,N-dimethylformamide (2 mL) was treated with methyl

bromoacetate (0.4 g, 2.8 mmol) and an excess of powdered NaOH (0.5 g, 12.5 mmol). The resulting yellow slurry was stirred vigorously for 24 h at room temperature. The reaction was acidified with 5 N HCl and extracted with diethyl ether (3 x 10 ml).
5 The combined ether layers were washed with H₂O (3 x 10 ml) and brine (1 x 10 ml), and then dried with Na₂SO₄. The ether solution was concentrated to a yellow oil that was purified by silica gel chromatography eluting with 19% (v/v) EtOAc and 2% acetic acid in hexanes. The resulting yellow liquid was dissolved in diethyl ether
10 (30 ml), washed with H₂O (3 x 10 mL) and brine (1 x 10 mL), and then dried with Na₂SO₄. The resulting solution was concentrated to a light yellow oil and dried in vacuo for 48 h. This yielded 7 as a waxy, off-white solid (80 mg, 97%). ¹H-NMR (CDCl₃/TMS, ppm): 0.87 (m, 12H, 4a'-, 8a'-, 12a'-, 13'-CH₃), 1.0 - 1.6 (m, 24H, 4'-, 8'-, 12'-CH, 1'-, 2'-, 5'-, 6'-, 7'-, 9'-, 10'-, 11'-CH₂, 2a-CH₃), 1.81 (m, 2H, 3-CH₂), 2.12, 2.14 (2 x s, 6H, 5a-, 8a-CH₃), 2.61 (t, J = 6.6 Hz, 2H, 4-CH₂), 4.59 (s, 2H, OCH₂), 6.53 (s, 1H, aryl CH); ¹³C-NMR (CDCl₃, ppm): 11.2, 16.1 (5a-, 8a-CH₃), 19.6, 19.7 (CH₃), 20.7, 21.0 (CH₂), 22.6, 22.7 (CH₃), 23.8 (2a-CH₃), 24.4, 24.8 (CH₂), 27.9 (CH), 31.2
15 (3-CH₂), 32.7, 32.8 (CH), 37.2, 37.4, 37.5, 39.4, 40.0 (CH₂), 66.8 (OCH₂), 74.8 (2-C), 113.8, 120.7, 123.1, 127.3 (aryl C), 147.1, 148.2 (aryl C=O), 175.3 (COOH); HRMS (CI, m/z): 475.377840 (M + H⁺, Calc. for C₃₀H₃₁O₄ 475.378136).

2,7,8-trimethyl-(2R-(4R,8R,12-trimethyltridecyl)
chroman-6-yloxy)acetic acid (8)




5

A solution of R,R,R- α -tocopherol (100 mg, 0.24 mmol) in N,N-dimethylformamide (5 mL) was treated with methyl bromoacetate (1.1 g, 7.4 mmol) and an excess of powdered NaOH (1.0 g, 25 mmol). The resulting yellow slurry was stirred vigorously
 10 for 24 h at room temperature. The reaction was acidified with 5 N HCl and extracted with diethyl ether (3 x 10 mL). The combined ether layers were washed with H₂O (3 x 10 mL) and brine (1 x 10 mL), and then dried with Na₂SO₄. The ether solution was concentrated to a yellow oil that was purified by silica gel
 15 chromatography eluting with 19% (v/v) EtOAc and 2% acetic acid in hexanes. The resulting yellow liquid was dissolved in diethyl ether (30 mL), washed with H₂O (3 x 10 mL) and brine (1 x 10 mL), and then dried with Na₂SO₄. The resulting solution was concentrated to a light yellow oil and dried in vacuo for 48 h. This yielded 8 as a
 20 waxy, off-white solid (110 mg, 97%). ¹H-NMR (CDCl₃/TMS, ppm): 0.87 (m, 12H, 4a'-, 8a'-, 12a'-, 13'-CH₃), 1.0 - 1.6 (m, 24H, 4'-, 8'-, 12'-CH, 1'-, 2'-, 3'-, 5'-, 6'-, 7'-, 9'-, 10'-, 11'-CH₂, 2a-CH₃), 1.81 (m, 2H, 3-CH₂), 2.12, 2.19 (2 x s, 6H, 7a-, 8a-CH₃), 2.61 (t, J = 6.6 Hz, 2H, 4-CH₂), 4.59 (s, 2H, OCH₂), 6.39 (s, 1H, aryl CH); ¹³C-NMR (CDCl₃,
 25 ppm): 11.9, 12.0 (7a-, 8a-CH₃), 19.6, 19.7 (CH₃), 20.7, 21.0 (CH₂), 22.6, 22.7 (CH₃), 23.8 (2a-CH₃), 24.4, 24.8 (CH₂), 27.9 (CH), 31.2

(3-CH₂), 32.7, 32.8 (CH), 37.2, 37.4, 37.5, 39.4, 40.0 (CH₂), 66.6 (OCH₂), 75.7 (2-C), 110.6, 117.7, 125.0, 126.3 (aryl C), 146.9, 148.7 (aryl C-O), 175.0 (COOH); HRMS (CI, m/z): 475.377962 (M + H⁺, Calc. for C₃₀H₅₁O₄ 475.378736).

5


2,8-dimethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy)acetic acid (9)



10 A solution of R,R,R- α -tocopherol (100 mg, 0.25 mmol) in N,N-dimethylformamide (5 mL) was treated with methyl bromoacetate (1.1 g, 7.4 mmol) and an excess of powdered NaOH (1.0 g, 25 mmol). The resulting yellow slurry was stirred vigorously for 24 h at room temperature. The reaction was acidified with 5 N
15 HCl and extracted with diethyl ether (3 x 10 ml). The combined ether layers were washed with H₂O (3 x 10 ml) and brine (1 x 10 ml), and then dried with Na₂SO₄. The ether solution was concentrated to a yellow oil that was purified by silica gel chromatography eluting with 19% (v/v) EtOAc and 2% acetic acid in
20 hexanes. The resulting yellow liquid was dissolved in diethyl ether (30 ml), washed with H₂O (3 x 10 mL) and brine (1 x 10 mL), and then dried with Na₂SO₄. The resulting solution was concentrated to a light yellow oil and dried in vacuo for 48 h. This yielded 9 as a waxy, off-white solid (111 mg, 98%). ¹H-NMR (CDCl₃/TMS, ppm):
25 0.87 (m, 12H, 4a'-, 8a'-, 12a'-, 13'-CH₃), 1.0 - 1.6 (m, 24H, 4'-, 8'-, 12'-CH, 1'-, 2'-, 3'-, 5'-, 6'-, 7'-, 9'-, 10'-, 11'-CH₂, 2a-CH₃), 1.81 (m, 2H,

3-CH₂), 2.15 (s, 3H, 8a-CH₃), 2.71 (t, J = 6.6 Hz, 2H, 4-CH₂), 4.59 (s, 2H, OCH₂), 6.48 (d, J = 3.0 Hz, 1H, aryl CH), 6.61 (d, J = 3.0 Hz, 1H, aryl CH); ¹³C-NMR (CDCl₃, ppm): 16.2 (8a-CH₃), 19.6, 19.7 (CH₃), 21.0 (CH₂), 22.6, 22.7 (CH₃), 24.0 (2a-CH₃), 24.4, 24.8 (CH₂), 27.9 (CH), 31.2 (3-CH₂), 32.7, 32.8 (CH), 37.2, 37.4, 37.5, 39.4, 40.0 (CH₂), 65.7 (OCH₂), 75.8 (2-C), 112.3, 115.6, 121.1, 127.5 (aryl C), 147.2, 149.9 (aryl C-O), 174.8 (COOH); HRMS (CI, m/z): 460.3552022 (M + H⁺, Calc. for C₃₀H₅₁O₄ 460.355262).


10 2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl)
chroman-6-yloxy)acetamide (10)



15 A solution of 1 (0.1 g, 0.2 mmol) in CH₂Cl₂ (5 mL) was treated with N-hydroxysuccinimide (26 mg, 0.23 mmol) and dicyclohexylcarbodiimide (46 mg, 0.23 mmol). After 2 min, a white precipitate formed. The resulting suspension was stirred for 2 h. The reaction stirred for an additional 6 h. The reaction mixture was
 20 cooled to -30 °C and filtered. The filtrate was concentrated and the resulting colorless oil was purified by silica gel chromatography eluting with EtOAc (35%, v/v) in hexanes. This yielded a white solid (75 mg, 76%). ¹H-NMR (CDCl₃/TMS, ppm): 0.87 (m, 12H, 4a'-, 8a'-, 12a'-, 13'-CH₃), 1.0 - 1.6 (m, 24H, 4'-, 8'-, 12'-CH, 1'-, 2'-, 3'-, 5'-, 6'-, 7'-, 9'-, 10'-, 11'-CH₂, 2a-CH₃), 1.81 (m, 2H, 3-CH₂), 2.10, 2.12, 2.16 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.59 (t, J = 6.6 Hz, 2H, 4-CH₂), 4.19 (s,
 25

2H, OCH₂), 6.36, 6.92 (2 x broad, 2H, NH); ¹³C-NMR (CDCl₃, ppm): 11.7, 11.8, 12.7 (5a-, 7a-, 8a-CH₃), 19.6, 19.7 (CH₃), 20.6, 21.0 (CH₂), 22.6, 22.7 (CH₃), 23.8 (2a-CH₃), 24.4, 24.8 (CH₂), 28.0 (CH), 31.2 (3-CH₂), 32.7, 32.8 (CH), 37.3, 37.4, 37.5, 39.4, 40.0 (CH₂), 5 70.9 (OCH₂), 74.9 (2-C), 117.8, 123.3, 125.4, 127.3 (aryl C), 146.5, 148.4 (aryl C-O), 172.1 (COOH); HRMS (CI, m/z): 488.409341 (M + H⁺, Calc. for C₃₁H₅₄NO₃ 488.410370).


10 Methyl2,5,7,8-tetramethyl-(2R-(4R,8R,12-
trimethyltridecyl) chroman-6-yloxy)acetate (11)



A solution of 1 (0.1 g, 0.2 mmol) in CH₂Cl₂ (5 mL) was treated with N,N-dimethylaminopyridine (26 mg, 0.23 mmol), 15 methanol (1 ml) and dicyclohexylcarbodiimide (46 mg, 0.23 mmol). After 2 min, a white precipitate formed. The resulting suspension was stirred for 6 h. The reaction mixture was cooled to -30 °C and filtered. The filtrate was concentrated and the resulting colorless oil was purified by silica gel chromatography eluting with EtOAc 20 (40%, v/v) in hexanes. This yielded a white solid (82 mg, 80%). ¹H-NMR (CDCl₃/TMS, ppm): 0.87 (m, 12H, 4a'-, 8a'-, 12a'-, 13'-CH₃), 1.0 - 1.6 (m, 24H, 4'-, 8'-, 12'-CH, 1'-, 2'-, 3'-, 5'-, 6'-, 7'-, 9'-, 10'-, 11'-CH₂, 2a-CH₃), 1.81 (m, 2H, 3-CH₂), 2.10, 2.16, 2.20 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.59 (t, J = 6.6 Hz, 2H, 4-CH₂), 3.85 (s, 3H, OCH₃), 25 4.32 (s, 2H, OCH₂); ¹³C-NMR (CDCl₃, ppm): 11.7, 11.8, 12.7 (5a-, 7a-, 8a-CH₃), 19.6, 19.7 (CH₃), 20.6, 21.0 (CH₂), 22.6, 22.7 (CH₃), 23.8

(2a-CH₃), 24.4, 24.8 (CH₂), 28.0 (CH), 31.2 (3-CH₂), 32.7, 32.8 (CH), 37.3, 37.4, 37.5, 39.4, 40.0 (CH₂), 50.2 (OCH₃), 69.8 (OCH₂), 74.9 (2-C), 117.6, 123.0, 125.6, 127.5 (aryl C), 147.6, 148.2 (aryl C-O), 169.8 (COOH); HRMS (CI, m/z): 503.408411 (M + H⁺, Calc. for C₃₂H₅₅O₄ 503.410036).

2-(N,N-(carboxymethyl)-2(2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy)acetic acid (12)



10

A solution of 1 (0.2 g, 0.4 mmol) in CH₂Cl₂ (5 mL) was treated with diethyl iminodiacetate (77 mg, 0.4 mmol) and O-7-azabenzotriazol-1-yl-N,N,N',N'-tetramethyuronium hexafluorophosphate (HATU) (46 mg, 0.23 mmol). After 12 h, the reaction mixture was concentrated to a paste and then purified by silica gel chromatography eluting with EtOAc (30%, v/v) in hexanes. This yielded the desired diester intermediate as colorless oil (150 mg, 55%). ¹H-NMR (CDCl₃/TMS, ppm): 0.87 (m, 12H, 4a'-, 8a'-, 12a', 13'-CH₃), 1.0-1.6 (m, 30H, 4', 8', 12'-CH₂, 1'-, 2'-, 3'-, 5'-, 6'-, 7'-, 9'-, 10'-, 11'-CH₂, 2a-CH₃), 1.78 (m, 2H, 3-CH₂), 2.08, 2.13, 2.17 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.58 (t, J = 6.8 Hz, 2H, 4-CH₂), 4.19, 4.22 (q, J = 7.4 Hz, 4H, OCH₂), 4.30, 4.33, 4.42 (3 x s, 6H, 2 x NCH₂, OCH₂); ¹³C-NMR (CDCl₃, ppm): 11.7, 11.8, 12.7 (5a-, 7a-, 8a-CH₃), 14.0 (CH₃), 19.6, 19.7 (CH₃), 20.6, 21.0 (CH₂), 22.6, 22.7 (CH₃), 23.8 (2a-CH₃), 24.4, 24.8 (CH₂), 28.0 (CH), 31.2 (3-CH₂), 32.7, 32.8 (CH), 37.3, 37.4, 37.5, 39.4, 40.0 (CH₂), 48.1, 49.4 (NCH₂), 61.2,


20

25

61.5 (OCH₂), 71.8 (OCH₂), 74.8 (2-C), 117.5, 122.9, 125.6, 127.4 (aryl C), 148.0, 148.1 (aryl C-O), 168.8, 169.0 (CO); MS (CI, m/z): 660 (M + H⁺, Calc. for C₃₉H₆₅NO₇ 659.47610).

A solution of the diester intermediate (0.15 g, 0.23 mmol) in ethanol (4 ml) was treated with 1 N NaOH (1 ml). The resulting cloudy mixture was stirred at 70 °C for 15 h. The reaction mixture was acidified with 1 N HCl and the ethanol was removed in vacuo. The resulting aqueous solution was extracted with CHCl₃ (5 x 20 ml) and the combined organic layers dried with Na₂SO₄. This yielded 12 (0.13 g, 52%) as a white solid. ¹H-NMR (CDCl₃/TMS, ppm): 0.87 (m, 12H, 4a⁻, 8a⁻, 12a⁻, 13'-CH₃), 1.0 - 1.6 (m, 24H, 4'-, 8'-, 12'-CH, 1'-, 2'-, 3'-, 5'-, 6'-, 7'-, 9'-, 10'-, 11'-CH₂, 2a-CH₃), 1.70 (m, 2H, 3-CH₂), 2.01, 2.05, 2.08 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.47 (m, 2H, 4-CH₂), 4.18 (m, 4H, 2 x NCH₂), 4.31 (m, 2H, OCH₂); ¹³C-NMR (CDCl₃, ppm): 11.5, 11.6, 12.4 (5a-, 7a-, 8a-CH₃), 19.4, 19.5 (CH₃), 20.6, 21.0 (CH₂), 22.6, 22.7 (CH₃), 23.8 (2a-CH₃), 24.4, 24.8 (CH₂), 28.0 (CH), 31.2 (3-CH₂), 32.4, 32.5 (CH), 37.0, 37.2, 37.5, 39.1, 40.0 (CH₂), 48.1, 49.4 (NCH₂), 71.1 (OCH₂), 74.8 (2-C), 117.5, 122.9, 125.4, 127.2 (aryl C), 147.8, 148.1 (aryl C-O), 168.8, 169.0 (CO); HRMS (CI, m/z): 604.420882 (M + H⁺, Calc. for C₃₅H₅₈NO₇ 604.421329).


2-(2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy))ethan-1-ol (13)



A solution of R,R,R- α -tocopherol (0.5 g, 1.16 mmol) in N,N-dimethylformamide (20 mL) was treated with iodoethanol (1.7 g, 10 mmol) and an excess of powdered NaOH (2.5 g, 63 mmol). The resulting yellow slurry was stirred vigorously for 24 h at room temperature. The reaction was acidified with 5 N HCl and extracted with diethyl ether (3 x 30 ml). The combined ether layers were washed with H₂O (3 x 30 ml) and brine (1 x 30 ml), and then dried with Na₂SO₄. The ether solution was concentrated to a yellow oil that was purified by silica gel chromatography eluting with 30% (v/v) EtOAc and 2% acetic acid in hexanes. The resulting yellow liquid was dissolved in diethyl ether (30 ml), washed with H₂O (3 x 20 mL) and brine (1 x 20 mL), and then dried with Na₂SO₄. The resulting solution was concentrated to a light yellow oil and dried in vacuo for 48 h. This yielded 13 as yellow oil (0.40 g, 73%). ¹H-NMR (CDCl₃/TMS, ppm): 0.87 (m, 12H, 4a'-, 8a'-, 12a'-, 13'-CH₃), 1.0 - 1.6 (m, 24H, 4'-, 8'-, 12'-CH, 1'-,2'-,3'-,5'-,6'-,7'-,9'-,10'-,11'-CH₂, 2a-CH₃), 1.81 (m, 2H, 3-CH₂), 2.07, 2.14, 2.16 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.59 (t, J = 6.6 Hz, 2H, 4-CH₂), 3.79 (m, 2H, OCH₂), 3.94 (m, 2H, OCH₂); ¹³C-NMR (CDCl₃, ppm): 11.7, 11.8, 12.7 (5a-, 7a-, 8a-CH₃), 19.6, 19.7 (CH₃), 20.6, 21.0 (CH₂), 22.6, 22.7 (CH₃), 23.8 (2a-CH₃), 24.4, 24.8 (CH₂), 28.0 (CH), 31.2 (3-CH₂), 32.7, 32.8 (CH), 37.3, 37.4, 37.5, 39.4, 40.0 (CH₂), 63.1, 69.2 (OCH₂), 75.0 (2-C), 117.8, 123.4, 126.4, 128.3 (aryl C), 149.2, 149.5 (aryl C-O); MS (CI, m/z): 475 (M + H⁺, Calc. for C₃₁H₅₄O₃ 474.40729).

2-(2,5,7,8-pentamethylchroman-6-yloxy)acetic acid


(14)



A solution of 2,2,5,7,8-pentamethyl-6-chroman-ol (0.3 g, 1.36 mmol) in N,N-dimethylformamide (20 mL) was treated with methyl bromoacetate (0.8 g, 5.3 mmol) and an excess of powdered NaOH (0.7 g, 18 mmol). The resulting yellow slurry was stirred vigorously for 24 h at room temperature. The reaction was acidified with 5 N HCl and extracted with diethyl ether (3 x 30 ml). The combined ether layers were washed with H₂O (3 x 30 ml) and brine (1 x 30 ml), and then dried with Na₂SO₄. The ether solution was concentrated to a yellow oil that was purified by silica gel chromatography eluting with 30% (v/v) EtOAc and 2% acetic acid in hexanes. The resulting yellow liquid was dissolved in diethyl ether (30 ml), washed with H₂O (3 x 20 mL) and brine (1 x 20 mL), and then dried with Na₂SO₄. The resulting solution was concentrated to a light yellow oil and dried in vacuo for 48 h. This yielded 14 as a white solid (0.31 g, 82%). ¹H-NMR (CDCl₃/TMS, ppm): 1.31 (s, 6H, CH₃), 1.81 (t, J = 7.8 Hz, 3 CH₂), 2.10, 2.16, 2.19 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.61 (t, J = 7.8 Hz, 2H, 4-CH₂), 4.39 (s, 2H, OCH₂); ¹³C-NMR (CDCl₃, ppm): 11.7, 11.8, 12.7 (5a-, 7a-, 8a-CH₃), 20.9, 26.8, 32.7 (alkyl), 69.1, (OCH₂), 72.9 (2-C), 117.5, 123.2, 125.5, 127.3 (aryl), 147.0, 148.6 (O-aryl), 173.8 (COOH); HRMS (CI, m/z): 279.159238 (M + H⁺, Calc. for C₁₆H₂₃O₄ 279.159634).

25

2,5,7,8-tetramethyl-(2RS-(4RS,8RS,12-trimethyltridecyl)
chroman-6-yloxy)acetic acid (15)




A solution of all racemic α -tocopherol (0.5 g, 1.16
 5 mmol) in N,N-dimethylformamide (20 mL) was treated with methyl
 bromoacetate (3.4 g, 8.3 mmol) and an excess of powdered NaOH
 (1.2 g, 30 mmol). The resulting yellow slurry was stirred vigorously
 for 24 h at room temperature. The reaction was acidified with 5 N
 HCl and extracted with diethyl ether (3 x 30 ml). The combined
 10 ether layers were washed with H₂O (3 x 30 ml) and brine (1 x 30
 ml), and then dried with Na₂SO₄. The ether solution was
 concentrated to a yellow oil that was purified by silica gel
 chromatography eluting with 19% (v/v) EtOAc and 2% acetic acid in
 hexanes. The resulting yellow liquid was dissolved in diethyl ether
 15 (30 ml), washed with H₂O (3 x 20 mL) and brine (1 x 20 mL), and
 then dried with Na₂SO₄. The resulting solution was concentrated to
 a light yellow oil and dried in vacuo for 48 h. This yielded 15 as a
 waxy, off-white solid (80%). ¹H-NMR (CDCl₃/TMS, ppm): 0.88 (m,
 12H, 4a', 8a', 12a', 13'-CH₃), 1.0 - 1.6 (m, 24H, 4', 8', 12'-CH₂, 1'-
 20 , 2'-, 3'-, 5'-, 6'-, 7'-, 9'-, 10'-, 11'-CH₂, 2a-CH₃), 1.84 (m, 2H, 3-CH₂),
 2.07, 2.14, 2.16 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.61 (t, J = 6.6 Hz, 2H,
 4-CH₂), 4.34 (s, 2H, OCH₂); ¹³C-NMR (CDCl₃, ppm): 11.5, 11.7, 12.6
 (5a-, 7a-, 8a-CH₃), 19.6, 19.7 (CH₃), 20.6, 21.3 (CH₂), 22.6, 22.8
 (CH₃), 23.8 (2a-CH₃), 24.5, 24.9 (CH₂), 29.0 (CH), 31.6 (3-CH₂),
 25 32.6, 32.8 (CH), 37.5, 37.8, 37.9, 39.5, 41.0 (CH₂), 69.3 (OCH₂),
 75.1 (2-C), 117.9, 123.3, 125.5, 127.3 (aryl C), 147.0, 148.0 (aryl

C-O), 173.9 (COOH); HRMS (CI, m/z): 489.394375 (M + H⁺, Calc. for C₃₁H₅₃O₄ 489.394383).


2,5,7,8-tetramethyl-(2R-(carboxy)chroman-6-yloxy))

5 acetic acid (16)



A solution of (-)-(R)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (0.34g, 1.36 mmol) in N,N-dimethylformamide (20 mL) was treated with methyl bromoacetate (0.8 g, 5.3 mmol) and an excess of powdered NaOH (0.7 g, 18 mmol). The resulting yellow slurry was stirred vigorously for 24 h at room temperature. The reaction was acidified with 5 N HCl and extracted with diethyl ether (3 x 30 ml). The combined ether layers were washed with H₂O (3 x 30 ml) and brine (1 x 30 ml), and then dried with Na₂SO₄. The ether solution was concentrated to a yellow oil that was purified by silica gel chromatography eluting with 30% (v/v) EtOAc and 2% acetic acid in hexanes. The resulting yellow liquid was dissolved in diethyl ether (30 ml), washed with H₂O (3 x 20 mL) and brine (1 x 20 mL), and then dried with Na₂SO₄. The resulting solution was concentrated to light yellow oil and dried in vacuo for 48h. This yielded 16 as a white solid (0.33g, 80%). ¹H-NMR (CDCl₃/TMS, ppm): 1.52 (s, 3H, 2a-CH₃), 2.10 (m, 2H, 3-CH₂), 2.12, 2.16, 2.19 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.56 (t, J = 6.5 Hz, 2H, 4-CH₂), 4.36 (s, 2H, OCH₂).

2,5,7,8-tetramethyl-2R-(2RS,6RS,10-trimethylundecyl)
chroman-6-yloxy)acetic acid (17)



5 A solution of 10g (40mmol) of (-)-(S)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid and 0.5g of p-toluenesulfonic acid monohydrate in 200 ml of methanol was stirred and refluxed for 4hr. After cooling, the solution was diluted with water and extracted with diethyl ether. The combined ether
 10 layers were washed with saturated aqueous sodium bicarbonate solution, H₂O, and brine (1 x 30 ml), and then dried with Na₂SO₄. The resulting solution was concentrated and dried in vacuo for 48 h. This yielded 10 g (95%) of methyl (-)-(S)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylate as a colorless solid which was
 15 used without further purification. ¹H-NMR (CDCl₃/TMS, ppm): 1.52 (s, 3H, 2a-CH₃), 2.10 (m, 2H, 3-CH₂), 2.12, 2.16, 2.19 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.56 (t, J = 6.5 Hz, 2H, 4-CH₂), 3.55 (s, 3H, OCH₃); MS (CI, m/z): 264.422 M + H⁺, Calc. for C₁₅H₂₀O₄ 265.3224.

To a solution of 2g (7.58mmol) of this ester in 7.5ml of
 20 N, N-dimethylformamide (DMF) was added 2.6 g (18.8mmol) of anhydrous granular potassium carbonate followed by 2.3 ml (20 mmol) of benzylchloride. The resulting slurry was stirred at RT for 41 h then poured into 50 ml of water and worked up with ether in the usual way. The product was freed of excess benzyl chloride at
 25 50° under high vacuum. There was obtained 2.69g (100%) of pure (TLC) (-)-(S)-6-benzyloxy-2,5,7,8-tetramethyl-chroman-2carboxylic

acid methyl ester as a yellow solid, m.p. 102-106°. The analytical specimen of this compound was prepared as a colorless solid m.p. 108-109° (from ether/methanol). ¹H-NMR (CDCl₃/TMS, ppm): 1.54 (s, 3H, 2a-CH₃), 2.01 (m, 2H, 3-CH₂), 2.14, 2.17, 2.19 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.51 (t, J = 6.7 Hz, 2H, 4-CH₂), 3.64 (s, 3H, OCH₃), 5.12 (s, 2H, 6-OCH₂), 7.15 (m, 5H, ArH); MS (CI, m/z): 355.232 M + H⁺, Calc. for C₂₂H₂₅O₄ 354.448.

A solution of 3.54g (10mmol) of the above ether ester, in 20 ml of toluene and 10ml of CH₂Cl₂ was stirred with cooling from dry ice/acetone bath while 12 ml (18 mmol) of 25% disobutylaluminum hydride in toluene (Texas Alkyls) was added dropwise, over 10 min. After stirring at ca. -70° for 30 min, the reaction mixture was cautiously decomposed (-70°) with 10 ml of MeOH. Following the addition of 50 ml of water and 50 ml of 1N aqueous H₂SO₄ solution, the mixture was warmed to RT, and worked up with ether in the usual way giving 3.2 g (100%) of crude aldehyde ((+) S-6-Benzyl oxy-2,5,7,8-tetramethylchroman-2-carbaldehyde) as a viscous oil which was purified by silica gel chromatography eluting with 19% (v/v) EtOAc in hexane. ¹H-NMR (CDCl₃/TMS, ppm) : 1.53 (s, 3H, 2a-CH₃), 2.11 (m, 2H, 3-CH₂), 2.24, 2.27, 2.29 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.481 (t, J = 6.7 Hz, 2H, 4-CH₂), 5.19 (s, 2H, 6-OCH₂), 7.20 (m, 5H, ArH), 9.6 (s, 1H, CHO); MS (CI, m/z): 325.332 M + H⁺, Calc. for C₂₁H₂₄O₃ 324.422.

A solution of 9.6g of pseudoionone was dissolved in 100 ml of 95% ethanol; after 0.68 g of sodium borohydride in ethanol had been added at room temperature, the mixture was stirred for 2 hr and then left standing overnight. The mixture was added to a solution of 2 g of sodium hydroxide in 500 ml of water. The mixture was extracted with ether, and the ether extract was washed

with water, dried, and concentrated. The distillation of the residual oil in vacuo gave a colorless oil (pseudoionol); bp 112-120°C/5mmHG. 7.7g (80%).


To a solution of 2.97g of pseudoionol in 10 ml of
5 acetonitrile, there were added, under stirring and while the temperature was kept below 30°C, 4.53g of triphenylphosphine hydrochloride which had been obtained by passing dry hydrogen chloride into a solution of triphenylphosphine in dry ether. After the mixture had been left standing overnight at room temperature,
10 the acetonitrile was removed under reduced pressure below 50°C. To the residue there were added 4.47 gm of (+) S-6-Benzyloxy-2,5,7,8-tetramethylchroman-2-carbaldehyde in 15 ml of dimethylformamide, and the mixture was stirred. When a clear solution was obtained, sodium methoxide prepared from 0.352 g of
15 sodium and 7 ml of anhydrous methanol was stirred in, drop by drop below 15°C. The reaction mixture was turned red by the ylid formed. After the addition was complete, stirring was continued for 30 min at 10°C; then the mixture was gradually heated to 80°C, when the red color disappeared. The product was poured into 200
20 ml of 50% aqueous methanol, dried, and concentrated in vacuo. The residual oil was dissolved in 20 ml of ether, and an ethereal solution of mercuric chloride was added until no more precipitate formed. When the precipitate was filtered and the filtrate was washed with water, dried and concentrated, to give 4.7 g of yellow
25 oil were obtained. The crude mixture of cis and trans alkene (MS (CI, m/z): 485.22 , M + H⁺, Calc. for C₃₄H₄₄O₂ 484.7255) was dissolved in 30 ml of ethyl acetate and 0.80 g of 5% palladium on carbon was added, and the mixture was shaken under 40 psi of H₂ for 30 hrs and then filtered through Celilte and rinsed well with

ethyl acetate. The filtrate was concentrated and purified by silica gel chromatography eluting with EtOAc in hexane (1:9) to give 2,5,7,8-tetramethyl -(2R-(2RS,6RS,10-trimethylundecyl))-6-chromanol (60% yield) ¹H-NMR (CDCl₃/TMS, ppm): 0.97 (m, 12H, 2a'-, 6a'-, 10a'-, 11'-CH₃), 1.1 - 1.7 (m, 20H, 2'-, 6'-,10'-CH, 1'-,3'-4'-,5'-,7'-,8'-,9'-CH₂, 2a-CH₃), 1.88 (m, 2H, 3-CH₂), 2.17, 2.19, 2.20 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.63 (t, J = 6.7 Hz, 2H, 4-CH₂); (MS (CI, m/z): 403.27 , M + H⁺, Calc. for C₂₇H₄₆O₂ 402.6632.

A solution of 2,5,7,8-tetramethyl -(2R-(2RS,6RS,10-trimethylundecyl))-6-chromanol (0.466 g, 1.16 mmol) in N,N-dimethylformamide (20 mL) was treated with methyl bromoacetate (3.4 g, 8.3 mmol) and an excess of powdered NaOH (1.2 g, 30 mmol). The resulting yellow slurry was stirred vigorously for 24 h at room temperature. The reaction was acidified with 5 N HCl and extracted with diethyl ether (3 x 30 ml). The combined ether layers were washed with H₂O (3 x 30 ml) and brine (1 x 30 ml), and then dried with Na₂SO₄. The ether solution was concentrated to a yellow oil that was purified by silica gel chromatography eluting with 19% (v/v) EtOAc and 2% acetic acid in hexanes. This yielded compound 17 in 76% yield. ¹H-NMR (CDCl₃/TMS, ppm): 0.97 (m, 12H, 2a'-, 6a'-, 10a'-, 11'-CH₃), 1.2 - 1.7 (m, 20H, 2'-, 6'-,10'-CH, 1'-,3'-4'-,5'-,7'-,8'-,9'-CH₂, 2a-CH₃), 1.92 (m, 2H, 3-CH₂), 2.18, 2.20, 2.23 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.68 (t, J = 6.8 Hz, 2H, 4-CH₂), 4.48 (s, 2H, OCH₂); MS (CI, m/z): 461.44, M + H⁺, Calc. for C₂₉H₄₈O₄ 460.700.

25

2,5,7,8-tetramethyl-2R-(2,6,10-trimethyl-1,3,5,9
decatetraen)chroman-6-yloxy) acetic acid (18)



5 To a solution of methyl (-)-(S)- 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylate (20 gms 0.075mole) in 50ml of dry DMF, imidazole (13 gm, 0.1911mole), and tert-butyldimethylsilylchloride (14 gm, 0.0933 mole) were added. The mixture was stirred at 23°C for 24 hr and then treated with ether and poured
 10 into 1N HCl. The organic extracts were dried (brine, Na₂SO₄) and concentrated in vacuo. The crude product was purified by flash chromatography (9:1 hexane :ethyl acetate) to yield 6-(dimethyl (1,1-dimethylethyl) silyl) - 2,5,7,8-tetramethyl-chroman-2-carboxylate (TBS protected methyl ester). . ¹H-NMR (CDCl₃/TMS, ppm) : 0.12(s, 6H). 1.102(s, 9H), 1.18 (s, 3H), 1.48 (s, 3H), 1.645 (s, 3H), 2.07(s, 3H), 2.2 (t, J = 6.5hz 2H), 2.48-2.7 (m, 2H) and 3.72(s,3H, OCH₃) (MS (CI, m/z): 379.32, M + H⁺, Calc. for C₂₁H₃₄O₄ 378.586.

A solution of 3.78 g(10mmol) of the above ether ester,
 20 in 20 ml of toluene and 10ml of CH₂Cl₂ was stirred with cooling from dry ice/acetone bath while 12 ml (18 mmol) of 25% disobutylaluminum hydride in toluene (Texas Alkyls) was added dropwise, over 10 min. After stirring at ca. -70° for 30 min, the reaction mixture was cautiously decomposed (-70°) with 10 ml of
 25 MeOH. Following the addition of 50 ml of water and 50 ml of 1N aqueous H₂SO₄ solution, the mixture was warmed to RT, and worked

up with ether in the usual way giving 3.2g (90%) of crude aldehyde ((+)-S-6-(dimethyl(1,1-dimethylethyl)silyl)-2,5,7,8-tetramethylchroman-2-carbaldehyde) as a viscous oil which was purified by silica gel chromatography eluting with 19% (v/v) EtOAc in hexane.

5 Concentration of the solution followed by drying under vacuo for 48 h yielded TBDS aldehyde (78%) as a solid of mp 66-68°C. ¹H-NMR (CDCl₃/TMS, ppm) : 0.12(s, 6H), 1.1(s, 9H), 1.38 (s, 3H), 1.64 (s, 3H), 2.12 (s, 3H), 2.16(s, 3H), 2.3-2.2 (m, 2H), 2.53 (m, 2H) and 9.82(d, J=1.4Hz, 1H); MS (CI, m/z): 349.40 M + H⁺, Calc. for
10 C₂₀H₃₂SiO₃ 348.560.

To a solution of 2.97 g of pseudoionol in 10 ml of acetonitrile, there were added, under stirring and while the temperature was kept below 30°C, 4.53 g of triphenylphosphine hydrochloride which had been obtained by passing dry hydrogen
15 chloride into a solution of triphenylphosphine in dry ether. After the mixture had then been left standing overnight at room temperature, the acetonitrile was removed under reduced pressure below 50°C. To the residue there were added 4.80 gm of ((+)-S-6-(dimethyl(1,1-dimethylethyl)silyl)-2,5,7,8-tetramethylchroman-2-
20 carbaldhyde) in 15 ml of dimethylformamide, and the mixture was stirred. When a clear solution was obtained, sodium methoxide prepared from 0.352 g of sodium and 7 ml of anhydrous methanol was stirred in, drop by drop below 15°C. The reaction mixture was turned red by the ylid formed. After the addition was complete,
25 stirring was continued for 30 min at 10°C; then the mixture was gradually heated to 80°C, when the red color disappeared. The product was poured into 200 ml of 50% aqueous methanol, dried, and concentrated in vacuo. The residual oil was dissolved in 20 ml of ether, and an ethereal solution of mercuric chloride was added


until no more precipitate formed. When the precipitate was filtered and the filtrate was washed with water, dried and concentrated, to give 4.7 g of yellow oil were obtained. The crude silyl ether mixture of cis and trans alkene was dissolved in THF and tetra-n-butylammoniumfluoride (0.031mole) was added. After being stirred at 23°C for 40 minutes, the mixture was poured into water and extracted into ether. The ether extract was dried concentrated and purified by silica gel chromatography eluting with EtOAc in hexane (1:9) to give 2,5,7,8-tetramethyl-2R- (2,6,10-trimethyl-1,3,5,9 E:Z decatetraen)- 6-chromanol (68% yield). ¹H-NMR (CDCl₃/TMS, ppm) : 1.28 (s, 3H, 2aCH₃), 1.65(s, 3H), 1.70(s,6H) 1.72 (s,3H), 1.9(m, 6H), 2.18 (s,3H), 2.35 (S, 6H), 2.53 (t, J = 6.6Hz, 2H, 4CH₂), 5.13 - 5.27 (m, 3H) and 6.44(m, 2H) ; MS (CI, m/z): 395.17 M + H⁺, Calc. for C₂₇H₃₈O₂ 394.60.

A solution of 2,5,7,8-tetramethyl-2R- (2,6,10-trimethyl-1,3,5,9 E:Z decatetraen)- 6-chromanol (0.457 g, 1.16 mmol) in N,N-dimethylformamide (20 mL) was treated with methyl bromoacetate (3.4 g, 8.3 mmol) and an excess of powdered NaOH (1.2 g, 30 mmol). The resulting yellow slurry was stirred vigorously for 24 h at room temperature. The reaction was acidified with 5 N HCl and extracted with diethyl ether (3 x 30 ml). The combined ether layers were washed with H₂O (3 x 30 ml) and brine (1 x 30 ml), and then dried with Na₂SO₄. The ether solution was concentrated to a yellow oil that was purified by silica gel chromatography eluting with 19% (v/v) EtOAc and 2% acetic acid in hexanes. The resulting liquid was dissolved in diethyl ether (30 ml), washed with H₂O (3 x 20 mL) and brine (1 x 20 mL), and then dried with Na₂SO₄. The resulting solution was concentrated and dried in vacuo for 48 h. This yielded compound 18 in 67% yield. ¹H-NMR (CDCl₃/TMS, ppm) : 1.24 (s,

3H, 2aCH₃), 1.63(s, 3H), 1.72(s,6H) 1.74 (s,3H), 1.92(m, 6H), 2.18 (s,3H), 2.29 (S, 6H), 2.43 (t, J = 6.6Hz, 2H, 4CH₂), 4.68 (s,2H, OCH₂), 5.10 - 5.27 (m, 3H) and 6.34(m, 2H) ; MS (CI, m/z): 452.24 M - H⁺, Calc. for C₂₇H₃₈O₂ 452.63.

5

3-(2,5,7,8-tetramethyl-(2R-(4R,8,12-trimethyltridecyl) chroman-6-yloxy)propyl-1-ammonium chloride (19)



10 A solution of 3-bromopropylamine hydrobromide (1.0 g, 4.6 mmol) in a 2:1 dioxane/H₂O (45 mL) was cooled to 0 °C and treated with K₂CO₃ (6.22 g, 45 mmol) and di-tert-butyl dicarbonate (1.5 g, 6.9 mmol). The reaction was stirred for 15 h while warming to room temperature. The dioxane was removed in vacuo and the
15 remaining aqueous mixture was acidified with 5 N HCl and extracted with ethyl acetate (5 x 25 mL). The combined organic layers were dried with MgSO₄ and yielded 3-bromo-N-(tert-butoxycarbonyl)propylamine as a colorless oil (0.93 g, 93 %). ¹H-NMR (CDCl₃/TMS, ppm): 1.41 (s 9H, CH₃), 2.02 (quintet, J = 6.4 Hz, 2H, CH₂), 3.23 (m, 2H, NCH₂), 3.41 (t, J = 6.6 Hz, CH₂Br), 4.8 (broad, 1H, NH); ¹³C-NMR (CDCl₃, ppm): 28.3 (CH₃), 30.7, 32.6, 38.9 (CH₂), 79.3 (quaternary C), 155.9 (CO); MS (CI, m/z): 239, 241 (M + H⁺ Calc. for C₈H₁₆BrNO₂ 237.03644).


25 A solution of R,R,R-α-tocopherol (0.5 g, 1.16 mmol) in N,N-dimethylformamide (15 mL) was treated with 3-bromo-N-(tert-butoxycarbonyl)propylamine (0.9 g, 3.8 mmol) and an excess of

powdered NaOH (0.32 g, 8 mmol). The resulting yellow slurry was stirred vigorously for 24 h at room temperature. The reaction was acidified with 5 N HCl and extracted with diethyl ether (3 x 30 ml). The combined ether layers were washed with H₂O (3 x 30 ml) and
5 brine (1 x 30 ml), and then dried with Na₂SO₄. The ether solution was concentrated to a yellow oil that was purified by silica gel chromatography eluting with EtOAc (10% v/v) in hexanes. This yielded desired ether as a colorless oil (0.45 g, 66%). ¹H-NMR (CDCl₃/TMS, ppm): 0.87 (m, 12H, 4a'-, 8a'-, 12a'-, 13'-CH₃), 1.0 -
10 1.6 (m, 33H, 4'-, 8'-, 12'-CH, 1'-, 2'-, 3'-, 5'-, 6'-, 7'-, 9'-, 10'-, 11'-CH₂, 2a-CH₃), 1.81 (m, 2H, 3-CH₂), 1.99 (quintet, J = 6.2 Hz, 2H, CH₂), 2.07, 2.14, 2.16 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.59 (t, J = 6.6 Hz, 2H, 4-CH₂), 3.43 (m, 2H, NCH₂), 3.73 (t, J = 5.7 Hz, 2H, OCH₂), 4.34 (s, 2H, OCH₂); ¹³C-NMR (CDCl₃, ppm): 11.7, 12.0, 12.9 (5a-, 7a-, 8a-
15 CH₃), 19.6, 19.7 (CH₃), 20.6, 21.0 (CH₂), 22.6, 22.7 (CH₃), 23.7 (2a-CH₃), 24.4, 24.8 (CH₂), 27.9 (CH), 31.2 (3-CH₂), 32.7, 32.8 (CH), 37.2, 37.4, 37.5, 39.3, 40.1 (CH₂), 70.2 (OCH₂), 74.8 (2-C), 117.5, 122.9, 125.5, 127.5 (aryl C), 147.5, 148.0 (aryl C-O), 156.0 (CO); MS (CI, m/z): 589 M + H⁺, Calc. for C₃₇H₆₅NO₄ 587.49136.

20 The above N-protected ether (0.1 g, 0.17 mmol) was dissolved 4 N HCl in dioxane (1 mL, 4 mmol) and stirred for 4 h. The dioxane was removed by blowing a stream of argon over the reaction mixture. The resulting material was dried in vacuo for 8 h yielding 19 as a white solid (82 mg, 99%). ¹H-NMR (CDCl₃/TMS, ppm): 0.87 (m, 12H, 4a'-, 8a'-, 12a'-, 13'-CH₃), 1.0 - 1.6 (m, 33H, 4'-, 8'-, 12'-CH, 1'-, 2'-, 3'-, 5'-, 6'-, 7'-, 9'-, 10'-, 11'-CH₂, 2a-CH₃), 1.81 (m, 2H, 3-CH₂), 1.99 (quintet, J = 6.2 Hz, 2H, CH₂), 2.07, 2.11, 2.15 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.29 (m, 2H, CH₂), 2.59 (t, J = 6.6 Hz, 2H, 4-CH₂), 3.43 (m, 2H, NCH₂), 3.79 (m, 2H, OCH₂) ¹³C-NMR
25

(CDCl₃, ppm): 11.8, 11.9, 12.7 (5a-, 7a-, 8a-CH₃), 19.6, 19.7 (CH₃), 20.6, 21.0 (CH₂), 22.6, 22.7 (CH₃), 23.9 (2a-CH₃), 24.4, 24.8 (CH₂), 28.0 (CH), 28.4 (CH₃), 31.2 (3-CH₂), 32.7, 32.8 (CH), 37.3, 37.4, 37.5, 39.4, 40.0 (CH₂), 74.8 (OCH₂), 75.0 (2-C), 117.5, 122.9, 126.0, 127.3 (aryl C), 147.8, 148.0 (aryl C-O); HRMS (CI, m/z): 487.438887 (M + H⁺, Calc. for C₃₂H₅₇NO₂ 487.438935).

2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl) chroman-3-ene-6-yloxy) acetic acid (20)



10

A solution of R,R,R,- α -tocopherol acetate (2 g, 4.2mmol) in anhydrous toluene (150 mL) was heated to reflux and then treated with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (0.96 g, 4.2 mmol) in 4 portions at 1 h intervals. The reaction was refluxed for 24 h. During this time the reaction mixture became a dark red color and then it precipitated a light colored solid. The reaction was cooled to room temperature, filtered, and the filtrate was concentrated. The resulting dark colored oil was purified by silica gel chromatography eluting with ethyl acetate (10%, v/v) in hexanes. This yielded the desired chromene acetate as a colorless oil (1.74g, 88%). ¹H-NMR (CDCl₃/TMS, ppm): 0.87 (m, 12H, 4a'-, 8a'-, 12a'-, 13'-CH₃), 1.0 - 1.6 (m, 24H, 4'-, 8'-, 12'-CH, 1'-,2'-,3'-,5'-,6'-,7'-,9'-,10'-,11'-CH₂, 2a-CH₃), 2.07, 2.13, 2.18 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.35 (s, 3H, CH₃CO-), 5.61, 6.52 (2 x d, J = 10.0 Hz, 2H, CH); ¹³C-NMR (CDCl₃, ppm): 11.5, 11.6, 13.1 (5a-, 7a-, 8a-CH₃),

25


14.1 (CH₃), 19.6, 19.7 (CH₃), 20.4, 21.4 (CH₂), 22.6, 22.7 (CH₃),
24.4, 24.8 (CH₂), 25.8 (2a-CH₃), 27.9 (CH), 30.8 (3-CH₂), 32.7, 32.8
(CH), 37.2, 37.4, 39.4, 41.0 (CH₂), 60.3 (2-C), 117.6, 119.7, 122.3,
122.6, 128.9, 129.6 (aryl and vinyl C), 141.2, 148.4 (aryl C-O),
5 169.4 (CO); HRMS (CI, m/z): 471.375799 M + H⁺, Calc. for C₃₁H₅₀O₃
470.375996.

A solution of the chromene acetate (1.0 g, 2.13 mmol)
in ethanol (20 mL) was treated with 2 N NaOH (20 mL) and stirred
at 60 °C for 90 min. The reaction mixture was cooled, acidified
10 with 5 N HCl, and the ethanol was removed in vacuo. The resulting
aqueous solution was extracted with ether and concentrated to a
light yellow oil that was purified by silica gel chromatography
eluting with ethyl acetate (15%, v/v) in hexanes. This yielded the
desired chromene-6-ol intermediate as a colorless oil (0.92 g, 98%).
15 ¹H-NMR (CDCl₃/TMS, ppm): 0.87 (m, 12H, 4a'-, 8a'-, 12a'-, 13'-
CH₃), 1.0 - 1.6 (m, 24H, 4'-, 8'-, 12'-CH, 1'-,2'-,3'-,5'-,6'-, 7'-,9'-,10'-
,11'-CH₂, 2a-CH₃), 2.14, 2.18, 2.19 (3 x s, 9H, 5a-, 7a-, 8a-CH₃),
5.63, 6.55 (2 x d, J = 10.0 Hz, 2H, CH); ¹³C-NMR (CDCl₃, ppm): 10.8,
11.6, 12.4 (5a-, 7a-, 8a-CH₃), 19.6, 19.7 (CH₃), 21.3 (CH₂), 22.6,
20 22.7 (CH₃), 24.4, 24.8 (CH₂), 25.2 (2a-CH₃), 27.9 (CH), 30.9 (3-
CH₂), 32.7, 32.8 (CH), 37.2, 37.4, 37.5, 39.3, 40.5 (CH₂), 50.8 (2-C),
116.2, 117.8, 123.1, 122.3, 123.0, 130.0 (aryl and vinyl C), 144.6,
145.3 (aryl C-O), 169.4 (CO); HRMS (CI, m/z): 428.365275 M + H⁺,
Calc. for C₂₉H₄₈O₂ 428.365431.

25 A solution of the chromene-6-ol intermediate (0.9 g, 2.1
mmol) in N,N-dimethylformamide (20 mL) was treated with methyl
bromoacetate (3.4 g, 8.3 mmol) and an excess of powdered NaOH
(1.2 g, 30 mmol). The resulting yellow slurry was stirred vigorously
for 24 h at room temperature. The reaction was acidified with 5 N


HCl and extracted with diethyl ether (3 x 30 ml). The combined ether layers were washed with H₂O (3 x 30 ml) and brine (1 x 30 ml), and then dried with Na₂SO₄. The ether solution was concentrated to a yellow oil that was purified by silica gel chromatography eluting with 19% (v/v) EtOAc and 2% acetic acid in hexanes. The resulting yellow liquid was dissolved in diethyl ether (30 ml), washed with H₂O (3 x 20 mL) and brine (1 x 20 mL), and then dried with Na₂SO₄. The resulting solution was concentrated to a light yellow oil and dried in vacuo for 48 h. This yielded 19 as a colorless (0.90 g, 88%). ¹H-NMR (CDCl₃/TMS, ppm): 0.87 (m, 12H, 4a'-, 8a'-, 12a'-, 13'-CH₃), 1.0 - 1.6 (m, 24H, 4'-, 8'-, 12'-CH, 1'-, 2'-, 3'-, 5'-, 6'-, 7'-, 9'-, 10'-, 11'-CH₂, 2a-CH₃), 2.07, 2.10, 2.19 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 4.37 (s, 2H, OCH₂), 5.62, 6.50 (2 x d, J = 10.0 Hz, 2H, CH); ¹³C-NMR (CDCl₃, ppm): 11.3, 11.5, 12.9 (5a-, 7a-, 8a-CH₃), 19.6, 19.7 (CH₃), 21.3 (CH₂), 22.6, 22.7 (CH₃), 24.4, 24.8 (CH₂), 25.6 (2a-CH₃), 27.9 (CH), 30.9 (3-CH₂), 32.7, 32.8 (CH), 37.2, 37.4, 37.5, 39.3, 40.9 (CH₂), 60.5 (OCH₂), 69.1 (2-C), 118.0, 119.8, 122.8, 122.9, 129.6, 19.8 (aryl and vinyl C), 147.5, 147.8 (aryl C-O), 173.4 (CO); HRMS (CI, m/z): 487.378731 M + H⁺, Calc. for C₃₁H₅₁O₄ 487.378736.

2-(2,5,7,8-tetramethyl-(2R-(4R,8,12-trimethyltridecyl)chroman-6-yloxy)triethylammonium sulfate (21)



A solution of 2-(2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy))ethan-1-ol (13) (0.1 g, 0.21 mmol) in anhydrous DMF (2 mL) and pyridine (0.6 mL) was treated sulfur trioxide-N,N-dimethylformamide complex (0.16 g, 1.0 mmol), and the resulting solution was stirred for 24 h. The reaction mixture was quenched with 1 N HCl and then extracted with CH₂Cl₂ (5 x 5 mL). Gaseous ammonia was bubbled through the CH₂Cl₂ solution for 10 min. The resulting solution was concentrated to a yellow paste and purified by silica gel chromatography eluting with MeOH (10%, v/v) and triethyl amine (2%) in CHCl₃. This yielded 21 as a yellow semi-solid (92 mg, 77%) ¹H-NMR (CDCl₃/TMS, ppm): 0.87 (m, 12H, 4a'-, 8a'-, 12a'-, 13'-CH₃), 1.0 - 1.6 (m, 33H, 4'-, 8'-, 12'-CH, 1'-, 2'-, 3'-, 5'-, 6'-, 7'-, 9'-, 10'-, 11'-CH₂, 2a-CH₃), 1.81 (m, 2H, 3-CH₂), 1.95 2.01, 2.05 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.45 (t, J = 6.6 Hz, 2H, 4-CH₂), 3.05 (m, 6H, NCH₂), 3.79 (m, 2H, OCH₂), 4.21 (m, 2H, OCH₂); ¹³C-NMR (CDCl₃, ppm): 9.46 (CH₃), 12.4, 12.6, 13.5 (5a-, 7a-, 8a-CH₃), 20.3, 20.4 (CH₃), 21.3, 21.7 (CH₂), 23.3, 23.4 (CH₃), 24.5 (2a-CH₃), 25.1, 25.5 (CH₂), 28.6 (CH), 31.9 (3-CH₂), 33.3, 33.4 (CH), 37.9, 38.1, 40.0, 40.8 (CH₂), 46.9 (NCH₂), 67.4, 71.9 (OCH₂), 75.5 (2-C), 118.3, 123.5, 126.5, 128.3 (aryl C), 148.5 (aryl C-O); HRMS (CI, m/z): 554.364102 M - NH₃, Calc. for C₃₁H₅₄O₆S 554.364119.

6-(2,5,7,8-tetramethyl-(2R-(4R,8,12-trimethyltridecyl)chroman)acetic acid (22)



A solution of R,R,R- α -tocopherol (1.0 g, 2.3 mmol) in anhydrous CH_2Cl_2 (25 mL) was cooled to 0 °C. Diisopropylethyl amine (2 mL, 11.6 mmol) was added followed by the dropwise addition of trifluoromethylsulfonic anhydride (5.0 g, 17.7 mmol).
5 The solution turned to a dark immediately and was allowed to warm to room temperature while stirring for 24 h. The reaction was quenched with H_2O and then was extracted with diethyl ether (2 x 100 mL). The combined ether layers were washed with 1 N HCl (50 mL), H_2O (50 mL), brine (50 mL), and then dried with MgSO_4 . The
10 ether solution was concentrated to a yellow oil and purified by silica gel chromatography eluting with ethyl acetate (3%, v/v) in hexane. This yielded the desired triflate intermediate as a yellow oil (1.3 g, quantitative). ^1H -NMR (CDCl_3/TMS , ppm): 0.87 (m, 12H, 4a'-, 8a'-, 12a'-, 13'- CH_3), 1.0 - 1.6 (m, 24H, 4'-, 8'-, 12'-CH, 1'-, 2'-, 3'-, 5'-, 6'-, 7'-, 9'-, 10'-, 11'- CH_2 , 2a- CH_3), 1.81 (m, 2H, 3- CH_2), 2.07, 2.13, 2.21
15 (3 x s, 9H, 5a-, 7a-, 8a- CH_3), 2.62 (t, $J = 6.6$ Hz, 2H, 4- CH_2); ^{13}C -NMR (CDCl_3 , ppm): 11.9, 13.2, 14.0 (5a-, 7a-, 8a- CH_3), 19.6, 19.7 (CH_3), 20.6, 21.0 (CH_2), 22.6, 22.7 (CH_3), 23.8 (2a- CH_3), 24.4, 24.8 (CH_2), 28.0 (CH), 31.2 (3- CH_2), 32.7, 32.8 (CH), 37.3, 37.4, 37.5, 39.4, 40.0 (CH_2), 75.6 (2-C), 118.4, 124.4, 126.7, 128.1 (aryl C),
20 139.6, 150.9 (aryl C-O); ^{19}F -NMR (CDCl_3 , ppm): -73.52; HRMS (CI, m/z): 563.337803 ($M + \text{H}^+$, Calc. for $\text{C}_{30}\text{H}_{49}\text{O}_6\text{F}_3\text{S}$ 563.338192).

A solution of the triflate (1.3 g, 2.31 mmol) in anhydrous DMF (23 mL) was treated with LiCl (0.98 g, 4.62 mmol),
25 triphenylphosphine (0.37 g, 1.4 mmol), 2,6-di-tert-butyl-4-methylphenol (2-3 crystals), tributyl(vinyl)tin (0.73 g, 2.31 mmol), and dichlorobis(triphenylphosphine)-palladium(II) (0.24 g, 0.35 mmol). This mixture was heated to 120 °C and stirred. After 2h, additional tributyl(vinyl)tin (0.73 g, 2.31 mmol). After 8 h, the

reaction was cooled to room temperature and added to a mixture of H₂O (50 mL) and diethyl ether (50 mL). The ether layer was washed with 1 N HCl (6 x 30 mL) and a saturated solution of KF (6 x 30 mL). The ether solution was dried with Na₂SO₄ and then concentrated to a dark oil. This material was purified by silica gel chromatography eluting with ethyl acetate (3%, v/v) in hexane yielding the 6-vinylchroman intermediate as a clear oil (0.38 g, 38%). ¹H-NMR (CDCl₃/TMS, ppm): 0.87 (m, 12H, 4a'-, 8a'-, 12a'-, 13'-CH₃), 1.0 - 1.6 (m, 24H, 4'-, 8'-, 12'-CH, 1'-,2'-,3'-,5'-,6'-,7'-,9'-,10'-,11'-CH₂, 2a-CH₃), 1.86 (m, 2H, 3-CH₂), 2.20, 2.24, 2.28 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.62 (t, J = 6.8 Hz, 2H, 4-CH₂), 5.18, 5.56 (2 x dd, J_{gem} = 2.3 Hz, J_{cis} = 11.2 Hz, J_{trans} = 18.7 Hz, 2H, =CH₂), 6.77 (dd, J = 18.7, 11.2 Hz, 1H, CH); ¹³C-NMR (CDCl₃, ppm): 11.9, 16.3, 17.2 (5a-, 7a-, 8a-CH₃), 19.7, 19.8 (CH₃), 20.8, 21.1 (CH₂), 22.6, 22.7 (CH₃), 23.9 (2a-CH₃), 24.5, 24.8 (CH₂), 28.0 (CH), 31.2 (3-CH₂), 32.7, 32.8 (CH), 37.3, 37.5, 37.5, 39.4, 40.1 (CH₂), 74.9 (2-C), 116.7, 119.0, 122.0, 129.8, 131.2, 132.8, 136.8 (aryl/vinyl C), 150.9 (aryl C-O); HRMS (CI, m/z): 440.401602 (M + H⁺, Calc. for C₃₁H₅₂O 440.401812).


A solution of the 6-vinylchroman intermediate (0.12 g, 0.27 mmol) in anhydrous THF (1 mL) was cooled to 0 °C and treated with 9-BBN (0.60 mL, 0.5 M in THF, 0.3 mmol). The reaction mixture was heated to reflux for 8 h. The reaction was quenched with water (1.5 mL) and treated with NaBO₃•4H₂O and the resulting slurry was stirred overnight. Diethyl ether (4 mL) and the reaction mixture were extracted with CH₂Cl₂ (2 x 20 mL). The organic layers were concentrated to a clear oil that was purified by silica gel chromatography eluting with ethyl acetate (50%, v/v) in hexane. This yielded the desired 6-(2-hydroxyethyl)chroman intermediate as

a colorless oil (30 mg, 24 %). ¹H-NMR (CDCl₃/TMS, ppm): 0.87 (m, 12H, 4a'-, 8a'-, 12a'-, 13'-CH₃), 1.0 - 1.6 (m, 24H, 4'-, 8'-, 12'-CH, 1'-,2'-,3'-,5'-,6'-,7'-,9'-,10'-,11'-CH₂, 2a-CH₃), 1.81 (m, 2H, 3-CH₂), 2.17, 2.24, 2.28 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.68 (t, J = 6.8 Hz, 2H, 4-CH₂), 3.01 (t, J = 7.5 Hz, 2H, Ar-CH₂), 3.74 (t, J = 7.5 Hz, 2H, OCH₂); ¹³C-NMR (CDCl₃, ppm): 12.0, 15.1, 16.0 (5a-, 7a-, 8a-CH₃), 19.6, 19.7 (CH₃), 20.6, 21.0 (CH₂), 22.6, 22.7 (CH₃), 23.8 (2a-CH₃), 24.4, 24.8 (CH₂), 28.0 (CH), 31.2 (3-CH₂), 32.7, 32.8 (CH), 37.3, 37.4, 37.5, 39.4, 40.0 (CH₂), 62.2 (OCH₂), 72.6 (2-C), 116.8, 122.3, 124.9, 132.4, 133.9 (aryl C), 150.1 (aryl C-O); HRMS (CI, m/z): 458.412154 (M + H⁺, Calc. for C₃₁H₅₄O₂ 458.412384).

A solution of pyridinium chlorochromate (32 mg, 0.1 mmol) in anhydrous CH₂Cl₂ (0.5 mL) was treated with a solution of the 6-(2-hydroxyethyl)chroman intermediate (32 mg, 0.07 mmol) in CH₂Cl₂ (0.5 mL). The reaction was stirred for 2 h at which time no starting material was visible by thin layer chromatography. Diethyl ether (2 mL) was added and the resulting solution was filtered through a thin pad of celite. The filtrate was concentrated and yielded a yellow oil (20 mg). This oil was dissolved in t-BuOH (0.5 mL) and treated with phosphate buffer (0.5 mL, 1 N, pH = 4.0), 2-methyl-2-butene (0.1 mL) and NaClO₂ (5.4 mg, 0.05 mmol). After stirring for 40 min, the reaction mixture was extracted with CHCl₃ (6 x 10 mL) and the combined organic layers were dried with Na₂SO₄. The CHCl₃ solution was concentrated to a yellow oil that was purified by preparative thin layer chromatography eluting with ethyl acetate (30%, v/v) and acetic acid (1%) in hexanes. This yielded 22 as colorless oil (20 mg, 63%). ¹H-NMR (CDCl₃/TMS, ppm): 0.87 (m, 12H, 4a'-, 8a'-, 12a'-, 13'-CH₃), 1.0 - 1.6 (m, 24H, 4'-, 8', 12'-CH, 1'-,2'-,3'-,5'-,6'-,7'-,9'-,10'-,11'-CH₂, 2a-CH₃), 1.81 (m, 2H, 3-CH₂),

2.17, 2.24, 2.28 (3 x s, 9H, 5a-, 7a-, 8a-CH₃), 2.66 (t, J = 6.8 Hz, 2H, 4-CH₂), 3.71 (s, 2H, CH₂COOH); ¹³C-NMR (CDCl₃, ppm): 12.0, 15.3, 16.2 (5a-, 7a-, 8a-CH₃), 19.6, 19.7 (CH₃), 20.6, 21.0 (CH₂), 22.6, 22.7 (CH₃), 23.8 (2a-CH₃), 24.4, 24.8 (CH₂), 28.0 (CH), 28.9, 31.2 (3-CH₂), 32.7, 32.8 (CH), 37.3, 37.4, 37.5, 39.4, 40.0 (CH₂), 72.6 (2-C), 117.1, 122.2, 124.9, 132.4, 132.7 (aryl C), 150.2 (aryl C-O), 179.2 (COOH); HRMS (CI, m/z): 472.391583 (M + H⁺, Calc. for C₃₁H₅₂O₃ 472.391644).

10 2,5,7,8-tetramethyl-(2R-(heptyl) chroman-6-yloxy)acetic acid (23)




A solution of hexyltriphenylphosphonium bromide (0.880g, 2.05mmol) in 11.2 ml of anhydrous DME was stirred at room temperature while 0.86 ml (2.06mmol) of 2.4 M n-butyl lithium in hexane was added. The resulting red solution was stirred for 2h at room temperature, then a solution of ((+)-S-6-Benzylloxy-2,4,7,8-tetramethylchroman-2-carbaldehyde (306 mg, 0.944 mmol) in 3 ml of anhydrous DME was added and stirring was continued for 3 h at 65-75°C. After cooling, the reaction mixture was poured into cold dilute H₂SO₄ and work up ether was carried out in the usual manner. The ether was concentrated in vacuo to afford the oily material. Product was isolated using column chromatography and eluted with chloroform to yield 46% of the product. The mixture of cis and trans alkene was dissolved in 30 ml of ethyl acetate and 50 mg of 5% palladium on carbon was added,

and the mixture was shaken under 40 psi of H₂ for 10 hrs and then filtered through Celilte and rinsed well with ethyl acetate. The filtrate was concentrated and purified by silica gel chromatography eluting with EtOAc in hexane (1:9) to give (2R) 2,5,7,8-tetramethyl-2-(heptyl)-6-chromanol (60% yield) ¹H-NMR (CDCl₃/TMS, ppm): 0.89 (s, 3H), 1.3-1.5 (m, 15H), 1.89 (m, 2H), 2.2 (s, 3H), 2.08(s, 3H), 2.23 (s, 3H) , and 2.48 (t, J =6.5 Hz, 2H); MS (CI, m/z): 305.35 M + H⁺, Calc. for C₂₀H₃₂O₂ 304.4746).

A solution of 2,5,7,8-tetramethyl-2-(heptyl) chromanol (0.353 g, 1.16 mmol) in N,N-dimethylformamide (20 mL) was treated with methyl bromoacetate (3.4 g, 8.3 mmol) and an excess of powdered NaOH (1.2 g, 30 mmol). The resulting yellow slurry was stirred vigorously for 24 h at room temperature. The reaction was acidified with 5 N HCl and extracted with diethyl ether (3 x 30 ml). The combined ether layers were washed with H₂O (3 x 30 ml) and brine (1 x 30 ml), and then dried with Na₂SO₄. The ether solution was concentrated to a yellow oil that was purified by silica gel chromatography eluting with 19% (v/v) EtOAc and 2% acetic acid in hexanes. The resulting liquid was dissolved in diethyl ether (30 ml), washed with H₂O (3 x 20 mL) and brine (1 x 20 mL), and then dried with Na₂SO₄. The resulting solution was concentrated and dried in vacuo for 48 h. This yielded compound 23 in 36% yield. ¹H-NMR (CDCl₃/TMS, ppm): ¹H-NMR (CDCl₃/TMS, ppm): 0.88 (s, 3H), 1.2-1.5 (m, 15H), 1.88 (m, 2H), 2.1 (s, 3H), 2.18(s, 3H), 2.2 (s, 3H) , 2.55 (t, J =6.5 Hz, 2H) and 4.78 (s, 2H); HRMS (CI, m/z): 363.2535 (M + H⁺, Calc. for C₂₂H₃₅O₄ 363.2541).


2,5,7,8-tetramethyl-(2R-(tridecyl) chroman-6-yloxy)
acetic acid (24)

The compounds 24 and 25 were synthesized in manner identical to the synthesis of 23 using appropriate phosphonium bromide.



¹H-NMR (CDCl₃/TMS, ppm): 0.83 (s, 3H), 1.25-1.57 (m, 27H), 1.88 (m, 2H), 2.1 (s, 3H), 2.18 (s, 3H), 2.20(s, 3H), 2.55 (t, J =6.6 Hz, 2H) and 4.48 (s, 2H) ; MS (CI, m/z): 447.14 M + H⁺, Calc. For C₂₈H₄₆O₄ 446.6732.


2,5,7,8-tetramethyl-(2R-(heptadecyl) chroman-6-yloxy)acetic acid
(25)



¹H-NMR (CDCl₃/TMS, ppm): 0.86 (s, 3H), 1.15-1.67 (m, 35H), 1.88 (m, 2H), 2.16 (s, 3H), 2.20 (s, 3H), 2.23(s, 3H), 2.55 (t, J =6.4 Hz, 2H) and 4.78 (s, 2H) ; MS (CI, m/z): 503.45 M + H⁺, Calc. For C₃₂H₅₄O₄ 502.781.

2,5,7,8-tetramethyl-2R-(4,8,-dimethyl-1,3,7
nonotrien) chroman-6-yloxy) acetic acid (26)

5




Compound 26 was synthesized in a manner identical to the synthesis of compound 18 using nerol instead of pseudoionol.

10 $^1\text{H-NMR}$ (CDCl_3/TMS , ppm) : 1.24 (s, 3H, 2aCH₃), 1.63(m, 1H), 1.68 (s,3H), 1.74(s,6H), 1.92(m, 6H), 2.18 (s,3H), 2.29 (S, 6H), 2.43 (t, J = 6.6Hz, 2H, 4CH₂), 4.68 (s, 2H, OCH₂), 5.64(m, 2H) and 5.27 (m, 1H) ; MS (CI, m/z): 413.24 M +H⁺, Calc. for C₂₆H₃₆O₄ 412.0115.

15

E,Z, RS, RS, RS-(phytyltrimethylbenzenethiol-6-yloxy)
acetic acid (27)

20



2,3,6-trimethylphenol (1.6 g, 11.8 mmol) was dissolved in 50 mL of anhydrous methanol which had been deoxygenated by bubbling with nitrogen. Ammonium thiocyanate (2.2 g, 28.9 mmol)

25 was added to this solution which was then cooled to 0 °C and bubbled with chlorine gas. The initially colorless homogeneous solution becomes pink and then green with the formation of a white precipitate. The solution was stirred for 1 h at 0 °C and then for a further hour at 20 °C. The dissolved chlorine was removed by

bubbling with nitrogen and the precipitate removed by filtration. Evaporation of the filtrate under reduced pressure followed by drying under high vacuum (0.1 torr) yielded 2.20 g (97%) of 2,3,5-Trimethyl-4-hydroxyphenylthiocyanate in a form pure enough for
5 the next step in the synthesis. An analytical sample was recrystallized from hexanes : white crystals, mp 100.3 ° C. ¹H NMR (CDCl₃) δ 7.2 (s, 1 H), 5.0 (s, 1 H) 2.4 (s, 3 H), 2.2 (s, 6 H).


2,3,5-Trimethyl-4-hydroxyphenylthiocyanate (2 g, 10.35 mmol) was dissolved in 100 mL of anhydrous ether containing 25
10 mL of anhydrous tetrahydrofuran. This solution was added dropwise over 1 h to 100 mL of anhydrous ether containing LiAlH₄ (0.9 g, 24 mmol) at room temperature. After a further hour at 20 ° C, the unreacted LiAlH₄ was destroyed by cooling the heterogeneous mixture to 0 °C and adding moist ether (50 mL), H₂O (50 mL), and 1
15 N HCl (50 mL). A further 50 mL of water was added and the organic phase was separated and washed with water (2 x 50 mL), NaHCO₃ solution (2 x 50 mL), water (2 x 50 mL), and saturated NaCl (50 mL). The organic phase was dried over anhydrous MgSO₄ and filtered and the solvent removed under reduced pressure. Silica gel
20 column chromatography with 5% ethyl acetate in hexane gave 1.8 g (90%) of 2,3,5-trimethyl-4-hydroxybenzenethiol as a white powder, mp 86 °C (Lit. ¹ mp 86 °C)

Solution of 2,3,5-trimethyl-4-hydroxybenzenethiol (3 g, 17.83 mmol), isophytol (4.8 g, 16.19 mmol), anhydrous zinc
25 chloride (1.2 g, 8.8 mmol) and 0.2 mL of glacial acetic acid in 30 mL of absolute ether was refluxed for 1 h. The solvent was then removed in vacuo at 50 ° C and the red oil obtained was dissolved in a mixture of 50 mL of petroleum ether and 20 mL of 70% aqueous methanol. The ether layer was dried (Na₂SO₄) and evaporated in

vacuo to give a red oil, which was purified by silica gel chromatography eluting with hexans:ether (9:1) to give 3g(38%) E.Z, RS, RS, RS-Phytyltrimethylhydroxybenzenethiol as yellow oil. ¹H NMR (CDCl₃) δ 7.11 (s, 1 H, Ar-H), 5.23 (t, 1 H, vinylic-H), 4.62 (s, 1 H, OH), 3.34 (d, 2 H, Ar-S-CH₂-), 2.41 (s, 3 H, Ar-CH₃), 2.19 (s, 3 H, Ar-CH₃), 2.18 (s, 3 H, Ar-CH₃), 0.83-1.92 (m, 39 H, Phytol chain).

A solution of phytyltrimethylhydroxybenzenethiol (3g, 6.7 mmol) in N, N-dimethyl-formamide (80 mL) was treated with methyl bromoacetate (7.4 g, 48.3 mmol) and an excess of powdered NaOH (7 g, 175 mmol). The resulting pink oil was stirred at RT for 24 h. The reaction mixture was acidified with 5 N HCl and extracted with ether (3 x 150 mL). The combined ether layers were washed with H₂O (3 x 150 mL) and brine (1 x 150 mL), and then dried (Na₂SO₄). The ether solution was concentrated to a yellow oil that was purified by silica gel chromatography eluting with 20% EtOAc in hexane to give 3 g (88%) of E.Z, RS, RS, RS-(phytyltrimethylbenzenethiol-6-yloxy)acetic acid as a yellow oil. ¹H NMR (CDCl₃) δ 10.90 (s, 1 H, COOH), 8.08 (s, 1 H, Ar-H), 5.30 (t, 1 H, vinylic-H), 4.35 (s, 2 H, CH₂COOH), 3.42 (d, 2 H, Ar-S-CH₂-), 2.34 (s, 3 H, Ar-CH₃), 2.25 (s, 3 H, Ar-CH₃), 2.22 (s, 3 H, Ar-CH₃), 0.83-1.94 (m, 39 H, Phytol chain). HRMS (CI, m/z): 504.362821(M+H⁺, Calc. for C₄₁H₈₄O₃S 504.363718).

(R)-2((2,5,7,8-tetramethyl-2-(3 propene methyl ester) chroman-6-yloxy)acetic acid (28)




To a slurry of (carbomethoxymethyl)triphenyl phosphonium bromide (1.8 gm, 4.32 mmol) in 12 ml of THF at °C was added 1.66 ml of n-BuLi (2.5M in hexane) dropwise. The resulting solution was removed to room temperature for 2h, and
5 then a solution of (+)S-6-(dimethyl(1,1-dimethylethyl)silyl)-2,5,7,8-tetramethyl chroman-2-carbaldhyde (1.31g, 3.76 mmol) in 7 ml THF was added via cannula. The solution was stirred at room temperature for 44hr and then 10 ml of 1N aq. HCl was added. The layer were separated and then aq. phase was extracted with ether (
10 3 X 15 ml). The combined organic layer were washed with brine, dried over Na₂SO₄ and filtered. After concentration of the filtrate, the crude alkene was purified by flash chromatography eluting with dichloromethane to give mixture of the cis and trans alkene in 93% yield. The silyl ether mixture of cis and trans alkene (3.76mmol)
15 was dissolved in THF and tetra-n-butylammoniumfluoride (0.041mole) was added. After being stirred at 23°C for 1.5h, the mixture was poured into water and extracted into ether. The ether extract was dried concentrated and purified by silica gel chromatography eluting with EtOAc in hexane (3:7) and both the cis
20 and trans isomer of 2,5,7,8-tetramethyl-2R-(3'propenemethyl ester)-6-chromanol were isolated and characterized (68% yield) ¹H-NMR (CDCl₃/TMS, ppm). 1.65 (s, 3H, 2a CH₃), 2.12 (m, 2H, 3CH₂), 2.39 (s, 9H, CH₃), 2.48 (m, 2H, 4 CH₂), 3.78 (s, 3H, OCH₃), 6.11 (d, 1H, CH=) and 7.13 (d, 1H, CH=).

25 A solution of 2,5,7,8-tetramethyl-2R-(3'propene methyl ester)6-chromanol (0.353 g, 1.16 mmol) in N,N-dimethylformamide (20 mL) was treated with methyl bromoacetate (3.4 g, 8.3 mmol) and an excess of powdered NaOH (1.2 g, 30 mmol). The resulting yellow slurry was stirred vigorously for 24 h at room temperature.

The reaction was acidified with 5 N HCl and extracted with diethyl ether (3 x 30 ml). The combined ether layers were washed with H₂O (3 x 30 ml) and brine (1 x 30 ml), and then dried with Na₂SO₄. The ether solution was concentrated to a yellow oil that was purified by silica gel chromatography eluting with 19% (v/v) EtOAc and 2% acetic acid in hexanes. The resulting liquid was dissolved in diethyl ether (30 ml), washed with H₂O (3 x 20 mL) and brine (1 x 20 mL), and then dried with Na₂SO₄. The resulting solution was concentrated and dried in vacuo for 48 h. This yielded compound 28 in 40% yield. ¹H-NMR (CDCl₃/TMS, ppm): 1.68 (s, 3H, 2a CH₃), 2.11 (m, 2H, 3CH₂), 2.36 (s, 9H, CH₃), 2.56 (m, 2H, 4 CH₂), 3.70 (s, 3H, OCH₃), 4.78 (s, 2H, OCH₂), 6.03 (d, 1H, CH=) and 7.03 (d, 1H, CH=); MS (CI, m/z): 337.24 M+H⁺, Calc. for C₁₈H₂₄O₆ 336.3867 .

15 2,5,7,8-tetramethyl-(2R-(propionate) chroman-6-yloxy)
 acetic acid (29)



The mixture of cis and trans alkene 2,5,7,8-tetramethyl-2R-(3 propene methylester)-6-chromanol was dissolved in 30 ml of ethyl acetate and 50 mg of 5% palladium on carbon was added, and the mixture was shaken under 40 psi of H₂ for 24 hrs and then filtered through Celilte and rinsed well with ethyl acetate. The filtrate was concentrated and purified by silica gel chromatography eluting with EtOAc in hexane (1:9) to give compound # 29. ¹H-NMR (CDCl₃/TMS, ppm): 1.62 (s, 3H, 2a CH₃), 2.0-2.3 (m, 6H, CH₂), 2.41


(s, 9H, CH₃), 2.53 (m, 2H, 4 CH₂), 3.67 (s, 3H, OCH₃) and 4.88 (s, 2H, OCH₂); MS (CI, m/z):339.34 M+H⁺, Calc. for C₁₈H₂₆O₆338.4025.

5

EXAMPLE 3

Synthesis of all-racemic 1-aza- α -tocopherol analogs:

Phytyltrimethylhydroquinone (31)




The solution of trimethylhydroquinone (30, 7.5 g, 49.28 mmol), isophytol (12 g, 40.47 mmol), anhydrous zinc chloride (3 g, 22.01 mmol) and 0.4 mL of glacial acetic acid in 60 mL of absolute ether was refluxed for 1 h. The solvent was then removed *in vacuo* at 50° C and the slurry obtained was dissolved in a mixture of 50 mL of petroleum ether and 20 mL of 70% aqueous methanol. The emulsion formed was destroyed by the addition of 20 mL of ether. The ether layer was dried (Na₂SO₄) and evaporated *in vacuo* to give a red solid paste that was triturated vigorously with 70 mL of petroleum ether. After cooling to -78°C, the suspension was centrifuged and the supernatant petroleum ether was decanted. Cold petroleum ether (10 mL) was added to the crystalline mass, and the operation was twice repeated to give 10 g (47%) of sticky white solid, which was used in the next step without further purification.

30

Phytyltrimethylhydroquinone diacetate (32)


5



The crude phytyltrimethylhydroquinone (31, 9 g, 20.1 mmol) was dissolved in dry pyridine (90 g) and acetic anhydride (90 g). After storage for 10 h at room temperature, the mixture was poured onto ice (200 mL) and extracted with ether (2 x 100mL). The ether solution was washed with 3N sulfuric acid (2 x 100 mL), 10% sodium bicarbonate solution (2 x 100mL), and again water (2 x 100 mL), dried (Na₂SO₄), and evaporated to yield 10.2g (95%) of diacetate (32) as a light yellow oil. The oil was used in the next step without further purification.

Trimethyl(3,7,11,15-tetramethyl-3-benzamidohexadecyl) hydroquinone diacetate (33)


20



To a mixture of benzonitrile (10 g, 96.97 mmol), concentrated sulfuric acid (10 g) and glacial acetic acid (40 mL) was added, with stirring at 0 ° C, the diacetate (32, 10 g, 19.43 mmol). The solution was stored for 10 h at room temperature, then poured onto ice (150 mL) and extracted with ether (3 x 100mL). The ether extracts were washed neutral with water (3 x 100 mL), and

saturated sodium bicarbonate solution, dried (Na_2SO_4) and evaporated *in vacuo*. The crude product (21 g) was chromatographed on silica gel eluting with petroleum ether:ether (9:1). The unchanged benzonitrile was first removed. Elution with
5 ether then afforded 11 g (88%) of product that was crystallized from petroleum ether to give analytical sample (33) m.p. 90-92 ° C (lit.1 94-95 ° C).

10 2,5,7,8-Tetramethyl-2(4,8,12-trimethyltridecyl)3,4-
dihydroquinolin-6(2H)-one (37)



15

To a solution of the diacetate (33, 13 g, 20.4 mmol) in 60 mL of methanol, solid potassium hydroxide (11 g) was added and the mixture was refluxed under argon for 45 min. After cooling, the solution was diluted with ice-water (100 mL), and extracted under carbon dioxide with ether (3 x 100 mL) yielding 10 g (88%) of crude hydroquinone (34).

A solution of this product (34, 10 g, 18.1 mmol) in absolute ether (110 mL) was added dropwise with stirring during 20 min. to a suspension of lithium aluminum hydride (20 g, 527 mmol) in absolute ether (110 mL). The mixture was refluxed for 14 h and then hydrolyzed under carbon dioxide by the dropwise addition of methanol (10mL) followed by 3N hydrochloric acid (30 mL). After extraction with ether (3 x 200 mL), the crude solid benzylamino derivative (35, 8.4 g, 86%) was obtained.


This material (35, 8.4 g, 15.6 mmol) was dissolved in glacial acetic acid (120 mL) and hydrogenated at 50 ° C and atmospheric pressure in the presence of 2 g of palladium on charcoal (5%) at room temperature for 22 h (or until the hydrogen
5 absorption ceased). After cooling, the catalyst was filtered off, and the solution was diluted with water (50 mL), extracted with ether (3 x 80 mL) and dried (Na₂SO₄).

To this dry and neutral ether solution of 36 was added fresh silver oxide (2.1 g, 8.93 mmol), and the suspension was
10 stirred for 14 h. After filtration under argon and evaporation, 4 g of the crude iminoquinone (37) was obtained, which was chromatographed on silica gel eluting with hexanes:ether (200:1) to yield 2.4 g (63%) of pure yellow oil. HMRS (cl, m/z): 428.389883 (M + H⁺, Calc. For C₂₉H₄₉NO 428.389241).

15


1-Aza- α -tocopherol (38)

20



The iminoquinone (37, 1.34 g, 3.133 mmol) in 10 mL of ether was hydrogenated at room temperature and atmospheric pressure in the presence of 190 mg of Lindlar's catalyst. After 20 h,
25 the catalyst was filtered off under argon and the filtrate was evaporated *in vacuo* to give 810 mg (60%) of crude red oil, which was used in the next step without further purification.

1-Aza- α -tocopherol-6-yloxy-acetic acid (39) and 1-Aza- α -tocopherol-6-yloxy-methyl acetate (40)




A solution of 1-Aza- α -tocopherol (38, 800 mg, 1.86 mmol) in DMF (30 mL) was treated with methyl bromoacetate (2.1 g, 13.4 mmol) and an excess of powdered NaOH (1.9 g, 48.4 mmol). The resulting yellow suspension was stirred vigorously for 24 h at room temperature. The reaction mixture was acidified with 5N HCl to pH6, and extracted with diethyl ether (3 x 30 mL). The combined ether layers were washed with water (3 x 40 mL), brine (1 x 40 mL), and then dried (Na₂SO₄). The ether solution was concentrated to a yellow oil that was purified by silica gel chromatography eluting with CH₂Cl₂:MeOH:Hac (97:2:1) to give 300 mg (33%) of sticky yellow solid (39). ¹H-NMR (CDCl₃, ppm) 4.30 (s, 2H, OCH₂), 3.30 (s, 1H, NH), 2.59 (t, 2H, Ar-CH₂), 2.18 (s, 3H, Ar-CH₃), 2.12 (s, 3H, Ar-CH₃), 2.00 (s, 3H, Ar-CH₃), 1.80-0.84 (m, 38H, Ar-CH₂CH₂, NCCH₃ and phytyl chain); ¹³C-NMR (CDCl₃, ppm): 12.01, 12.77, 12.96, 19.60, 19.67, 19.72, 21.09, 22.60, 22.71, 24.42, 24.79, 26.56, 27.95, 32.11, 32.74, 37.26, 37.37, 37.42, 37.55, 37.65, 39.34, 41.36, 50.92, 69.50 (aliphitic C), 117.69, 118.55, 125.99, 126.39, 138.07, 146.05 (Ar-C), 173.18 (COOH); (HRMS (CI,m/z): 488.411055 (M + H⁺, Calc for C₃₁H₅₃NO₃ 488.410370) and 150 mg (17%) of yellow oil (40). ¹H-NMR (CDCl₃/TMS, ppm) 4.31 (s, 2H, OCH₂), 3.85 (s, 3H, CO₂CH₃), 3.32 (s, 1H, NH), 2.61 (t, 2H, Ar-CH₂), 2.23 (s, 3H, Ar-CH₃), 2.17 (s, 3H, Ar-CH₃), 2.01 (s, 3H, Ar-CH₃),

1.81-0.86 (M, 38H, Ar-CH₂CH₂, NCCH₃ and phytyl chain); ¹³C-NMR (CDCl₃, ppm) 11.96, 12.67, 12.90, 19.57, 19.63, 19.69, 21.06, 21.95, 22.57, 22.68, 24.38, 24.74, 26.49, 27.91, 32.25, 32.67, 32.70, 37.21, 37.33, 37.53, 39.31, 41.68, 50.43, 51.87, 69.97, 5 (aliphitic C), 116.98, 117.72, 126.01, 126.36, 138.43, 146.18 (Aryl C), 169.83 (C=O); HRMS (CI, m/z): 502.425330 (M + H⁺, Calc. for C₃₂H₅₅NO₃ 502.426020).

1-Aza-N-methyl- α -tocopherol-6-yloxy-methyl acetate

10 (41)




15

Following the literature procedure 2, a mixture of powdered KOH (500 mg, 7.77 mmol) in DMSO (30 mL) was stirred at 0°C for 5 min. The methyl acetate (40, 1.3 g, 23.32 mmol) was added, followed immediately by the addition of CH₃I (3.3 g, 23.32 mmol). Stirring was continued for 0.5 h (0°C) after which the mixture was poured into water. Extracts (CH₂Cl₂, 3 x 40 mL) of the final mixture were combined, washed with water (40 mL), brine (40 mL), dried (MgSO₄) and then evaporated. The resulting yellow oil was chromatographed over silica gel eluting with 5% ETOAC in 25 hexane to give 810 mg (60%) of light yellow oil. ¹H-NMR (CDCl₃/TMS, ppm) 4.34 (s, 2H, OCH₃), 3.84 (s, 3H, CO₂CH₃), 2.55 (t, 2H, Ar-CH₂), 2.49 (s, 3H, NCH₃), 2.24 (s, 3H, Ar-CH₃), 2.20 (s, 3H, Ar-CH₃), 2.13 (s, 3H, Ar-CH₃), 1.82-0.82 (m, 38H, Ar-CH₂CH₂, NCCH₃ and phytyl chain); ¹³C-NMR(CDCl₃, ppm) 11.72, 13.12, 14.27, 19.55,

19.68, 20.93, 22.57, 22.66, 22.88, 24.35, 24.74, 25.33, 25.37, 27.90, 32.59, 32.71, 37.23, 37.33, 37.51, 37.63, 38.49, 39.06, 39.29, 51.14, 69.57 (aliphitic C), 125.34, 126.36, 127.42, 130.32, 143.89, 150.33 (Ar-C), 169.73 (C=O). The compound **41** was used
 5 in the next step without further purification.

1-Aza-N-methyl- α -tocopherol-6-yloxy]- acetic acid (**42**)


10



To the mixture of the ester (**41**, 740 mg, 14.34 mmol) in ethanol (34 mL) was added dropwise 2N NaOH (9 mL, 10eq. 14.34
 15 mmol). After stirring the light yellow solution at room temperature for 4h, the reaction mixture was acidified with 2N HCl to pH6, and then extracted with EtOAc (3 x 100 mL) and the combined organic layers were washed with water (2 x 100 mL), brine (1 x 100 mL), dried (MgSO₄), and evaporated to give a light yellow oil. The oil
 20 was chromatographed over silica gel eluting with 1% HOAc, 30% EtOAc in hexans to give 650 mg (90%) of the product (**42**) as a colorless oil. ¹H-NMR (CDCl₃/TMS, ppm) 10.43 (s, 1H, CO₂H), 4.37 (s, 1H, OCH₂), 2.51 (t, 2H, Ar-CH₂), 2.43 (s, 3H, NCH₃), 2.22 (Ar-CH₃), 2.12 (s, 3H, Ar-CH₃), 1.81-0.80 (m, 38H, Ar-CH₂CH₂, NCCH₃ and phytyl chain); ¹³C-NMR (CDCl₃, ppm): 11.77, 13.18, 14.28, 19.68, 19.73, 20.80, 20.96, 22.62, 22.72, 23.00, 24.00, 24.41, 24.80, 25.37, 27.80, 32.77, 37.28, 37.30, 37.74, 38.00, 39.00, 39.35, 54.69, 69.17 (aliphitic C), 125.11, 126.55, 127.20, 130.63,
 25

142.00, 149.60 (Ar-C), 173.62 (COOH); HRMS (CI, m/z):
502.426327 (M + H⁺, Calc. For C₃₂H₅₅NO₃ 502.426020).

5 6-(2,4-Dinitrophenylazo(2,5,7,8-tetramethyl-2-(4,8,12-
trimethyltridecyl)-1,2,3,4-tetrahydroquinoline (43)



10

2,4-dinitrophenylhydrazine (1.95 g, 9.82 mmol) was
dissolved in 34 mL of hot absolute ethanol and 3.4 mL of
concentrated sulfuric acid was carefully added. The hot red
15 solution was cooled to room temperature and the iminoquinone
(37, 1.00 g, 2.34 mmol) in 12 mL of absolute ethanol was added
with stirring. The mixture was allowed to stand at room temperature
for 70 h, then diluted with 120 mL of water and extracted with ether
(3 x 100 mL). The combined ether extracts were washed neutral
20 with water (6 x 100 mL), dried (NaSO₄), and evaporated *in vacuo* to
give 2.9 g of a partly crystalline dark violet mass. This product was
chromatographed over silica gel eluting with 5% ether in petroleum
ether to yield 1.35 g (95%) of violet crystals (43), m.p. 72-73 °C
(lit.¹ 73-75). HRMS (CI, m/z): 608.417199 (M + H⁺, Calc. For
25 C₃₅H₅₃N₅O₄ 608.417581).

EXAMPLE 4**Cell Culture Conditions**

All test cell lines were cultured at 37°C in 5% CO₂ in standard media supplemented with fetal calf serum, using established standard conditions. Plastic adherent cells were disassociated with trypsin, washed, counted, and used directly in experiments. All cells were examined routinely to verify no mycoplasma contamination.

10

EXAMPLE 5**Solubility and Dilution of Novel Tocopherol and Tocotrienol Compounds**

15

All compounds were handled as if they were light sensitive (photodegradable). All compounds were initially dissolved in absolute ethanol and subsequently diluted to a final concentration of 0.5% ethanol with the appropriate media.

20

EXAMPLE 6**Determination of Effective Concentration (EC₅₀) to Induce Apoptosis**

25

Whereas the parental non-structurally modified forms of tocopherols do not exhibit effective apoptotic properties against a battery of tumor cells, fifteen out of twenty-nine RRR- α -tocopherol compounds and two out of five 1-aza- α -tocopherol analogs, structurally modified via ether linked moieties of different

composition and size were extremely effective at inducing tumor cells to undergo apoptosis while having no apoptotic inducing properties on normal cells. Compounds 1, 2, 3, 7, 8, 9, 12, 15, 17, 19, 20, 21, 22, 25, 26, 27, 39, and 42 exhibit effective growth inhibitory (apoptotic inducing) properties specific for human cancer cells from a wide variety of cell lineages, including (i) breast (estrogen responsive Michigan Cancer Foundation human breast cancer cell line number 7, MCF-7 McGuire; non-estrogen responsive M.D. Anderson metastatic breast human cancer cell line, MDA-MB-435; and, estrogen non-responsive M.D. Anderson metastatic human breast cancer cell line, MDA-MB-231); (ii) prostate (androgen responsive human prostate cancer cell line, LnCaP and the androgen non-responsive human prostate cancer cell line, PC-3 and the DU-145 cell line); (iii) promyelocytic leukemia cells (human Promyelocytic Leukemia Cell Line, HL-60), lymphoid cell lines Jurkat and HL-60; (iv) cervical (human cervical cancer cell line, ME-180); (v) ovarian (human ovarian cancer cell line, C-170 cells); (vi) endometrial (human endometrial cancer cell line, RL-95-2 cells); (vii) colon cell lines DLD-1; and (viii) lung cell line A-549. Normal primary breast cells (normal primary early passage human mammary epithelial cells, HMEC) and immortalized, non-tumorigenic mammary cells (Michigan Cancer Foundation immortalized but non-tumorigenic human mammary number 10A cells, MCF-10A) do not undergo apoptosis when cultured with the above pharmacodynamically designed forms of tocopherol.

The effective therapeutic dose of novel reagents for controlling cancer growth is referred to as the growth inhibitory concentration (IC_{50}) or effective concentration (EC_{50}) that blocks 50% cancer growth via DNA synthesis inhibition, cell cycle blockage

and/or cell death. The apoptotic EC_{50} for a battery of test cancer cells for the twenty-nine novel RRR- α -tocopherol compounds and two of the five 1-aza- α -tocopherol analogues of this invention are presented in Tables 1 and 2.

TABLE 1
Apoptosis Induced by Novel Tocopherol Compounds (EC₅₀ range μ g/ml)

Cell Type	VES	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Breast Cancer																
HMEC	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	NT
MCF-10A	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	NT
MDA-MB-435	5-10	5-10	5-10	5-10	5-10	5-10	5-10	5-10	5-10	5-10	5-10	5-10	5-10	5-10	5-10	20-30
MDA-MB-231	5-10	5-10	5-10	5-10	5-10	5-10	5-10	5-10	5-10	5-10	5-10	5-10	5-10	5-10	5-10	20-30
MCF-7	10-20	5-10	20-30	20-30	5-10	5-10	5-10	10-20	10-20	10-20	5-10	5-10	5-10	5-10	5-10	20-30
T47D	N	N	N	N	N	N	N	N	NT	NT	NT	NT	NT	NT	NT	NT
Cervical																
ME-180	10-20	1-5	5-10	10-20	N	N	N	5-10	5-10	5-10	N	N	5-10	N	N	N
Ovarian																
C-170	N	10-20	10-20	10-20	N	N	N	10-20	10-20	N	N	N	10-20	N	N	N
Endometrial																
RL-95-2	10-20	10-20	10-20	10-20	N	N	N	5-10	1-5	5-10	N	N	5-10	N	N	N
Prostate																
PREC	N	N	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
LnCap	5-10	5-10	5-10	5-10	N	N	N	2.5-5	5-10	5-10	N	N	>20-30	NT	N	NT
PC-3	10-20	5-10	5-10	5-10	N	N	N	5-10	5-10	5-10	NT	N	10-20	N	N	NT
DU-145	10-20	5-10	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
Colon																
HT-29	5-10	10-20	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
DLD-1	10-20	10-20	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
Lung																
A-549	20-30	10-20	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
Lymphoid Cells																
Myeloma	10-20	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
Raji	10-20	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
Ramos	10-20	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
Jurkat	10-20	10-20	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
HL-60	10-20	5-10	10-20	10-20	N	N	N	5-10	10-20	10-20	N	N	20-30	N	N	NT

EC₅₀ 50 μ g/ml of tocopherol compounds 1-29 is causing 50% apoptosis; N = No apoptosis when treated for 2 days with 1-60 EC₅₀ μ g/ml of tocopherol compounds 1-29; NT = Not tested; * = compounds exhibiting toxicity.

TABLE 2

Apoptosis Induced by Novel Tocopherol Compounds (EC_{50} range $\mu\text{g/ml}$)

Cell Type	16	17	18	19	20	21	22	23	24	25	26	27	28	29	39	42	43
<u>Breast Cancer</u>																	
HMEC	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
MCF-10A	NT	N	NT	N	N	N	NT	N	NT	N	N	NT	NT	NT	NT	NT	NT
MDA-MB-435	N	NT	N	10-20	10-20	N	NT	N	N	N	20-40	NT	NT	NT	10-20	10-20	PPT.
MDA-MB-231	N	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
MCF-7	N	10-20	N	10-20	5-10	N	15-20	N	N	N	N	10-20	NT	NT	NT	NT	NT
T47D	NT	10-20	NT	N	5-10	NT	NT	NT	NT	NT	N	NT	NT	NT	NT	NT	NT
<u>Cervical</u>																	
ME-180	NT	20-30	N	1-5	1-5	1-5	NT	NT	NT	N	*	NT	NT	NT	NT	NT	NT
<u>Ovarian</u>																	
C-170	NT	20-30	N	1-5	*	N	NT	NT	NT	N	20-30	NT	NT	NT	NT	NT	NT
<u>Endometrial</u>																	
RL-95-2	NT	NT	NT	NT	NT	N	NT	NT	NT	N	20-30	NT	NT	NT	NT	NT	NT
<u>Prostate</u>																	
PREC	NT	NT	N	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
LnCaP	NT	10-20	NT	5-10	5-10	N	NT	NT	N	N	10-20	10-20	NT	NT	NT	NT	NT
PC-3	NT	NT	NT	N	5-10	N	NT	N	N	20-30	N	NT	NT	NT	NT	NT	NT
DU-145	NT	NT	NT	5-10	5-10	N	NT	N	N	20-30	N	NT	NT	NT	NT	NT	NT
<u>Colon</u>																	
HT-29	NT	N	N	NT	NT	NT	NT	N	NT	N	N	NT	NT	NT	NT	NT	NT
DLD-1	NT	NT	NT	NT	NT	NT	NT	NT	N	N	20-40	NT	NT	NT	NT	NT	NT
<u>Lung</u>																	
A-549	NT	N	N	20-30	20-30	NT	NT	NT	NT	NT	N	NT	NT	NT	NT	NT	NT
<u>Lymphoid Cells</u>																	
Myeloma	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
Raji	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
Ramos	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
Jurkat	NT	10-20	N	10-20	10-20	NT	NT	NT	NT	NT	20-30	NT	NT	NT	NT	NT	NT
HL-60	NT	10-20	N	10-20	10	NT	NT	NT	NT	NT	N	NT	NT	NT	NT	NT	NT

EC_{50} $\mu\text{g/ml}$ of tocopherol compounds 1-29 inducing $\geq 50\%$ apoptosis; N = No apoptosis when treated for 2 days with 1-60 EC_{50} $\mu\text{g/ml}$ of tocopherol compounds 1-29; NT = Not tested; * = compounds exhibiting toxicity.

EXAMPLE 7

Bioassay for Apoptosis

Cells were cultured at 1.5×10^5 cells/well in 12 well
5 plates. Cells were allowed to adhere overnight, then incubated with
novel test compounds at 0.01, 0.1, 1, 5, 10 & 20 $\mu\text{g/mL}$ for 1, 2 and
3 days. After treatment, cells (floating + trypsin released adherent
cells) were pelleted, washed and stained with 2 $\mu\text{g/ml}$ DAPI (4',6-
diamidine-2'-phenylindole dihydrochloride) in 100% methanol for
10 15 minutes at 37°C and/or TUNEL stained, then viewed using a Zeiss
ICM 405 microscope. Cells whose nucleus contained clearly
condensed or fragmented chromatin were scored as apoptotic.
Data are presented as percent cells undergoing apoptosis.

15

EXAMPLE 8

Bioassay for DNA synthesis arrest

To assay DNA synthesis, all cells were used at $2.5 \times$
20 $10^5/\text{ml}$. Cells were treated with each of the compounds 1-29
(Tables 1 and 2) at concentrations of 0.01, 0.1, 1, 5, 10 and 20
 $\mu\text{g/ml}$, and 200 μl of each treatment group were plated in
quadruplicate in a 96 well culture plate (Corning, Corning NY).
Experiments were done in duplicate, one plate used for viability
25 testing and the other plate for examination of $^3\text{H-TdR}$ uptake to
monitor DNA synthesis. Plates were cultured for 48 hours at 37°C,
5% CO_2 . Eight hours prior to the end of incubation, $^3\text{H-TdR}$ was
added to one of the duplicate plates and incubation continued for 8
hours. The cells were then harvested (trypsinization was required

to harvest adherent cells), and isotope uptake was determined as counts per minute (cpm). For viability studies, at the end of the incubation, the cells were removed from the wells and viability checked by the Trypan Blue Exclusion method. Percent viability and
5 percent DNA synthesis in comparison to untreated or vehicle treated cells of each treatment group were calculated.

EXAMPLE 9

10

Bioassay for Cell Cycle Arrest

The cells were cultured with novel test agents for 2-3 days, fixed in 95% ethanol and stained with propidium iodide overnight. DNA content was determined using a Coulter Epics Elite
15 Flow Cytometer with an argon laser setting of 488 nm. Cell size was measured simultaneously, and data were analyzed as to percent cells in each cell cycle phase using the Coulter Multicycle Program.

20

EXAMPLE 10

Bioassay for Cellular Differentiation

To determine if the novel compounds were inducing cellular differentiation, the cells were cultured on cover slips, fixed
25 in 95% ethanol and stained with a lipid specific stain for detection of milk lipids. Additionally, cells were examined by immunohistology and by Western analyses for presence of milk protein casein, using polyclonal antibodies produced in the lab.

EXAMPLE 11

DNA Synthesis Arrest Effects

The cells were cultured for 48 hours, pulsed 8 hours
5 with tritiated thymidine, harvested and counted. Data are presented
as counts per minute. Verification of DNA synthesis arrest is
determined by reduced tritiated thymidine uptake by cells treated
with test compounds. Further verification of DNA synthesis arrest is
determined by propidium iodide staining and standard cell cycle
10 analyses.

EXAMPLE 12

15 Mechanisms of Induction of Apoptosis

The mechanism of induction of apoptosis by these
compounds appears to involve three distinct apoptotic signaling
pathways; namely, activation of latent transforming growth factor-
beta (TGF- β), activation of the Fas/Fas ligand signaling pathways,
20 and signaling by the stress kinase (c-Jun N-terminal Kinase)
pathway.

TGF- β s are potent growth inhibitory molecules that are
known to inhibit cell growth by inhibition of DNA synthesis arrest
and by induction of apoptosis. TGF- β s are involved only in
25 induction of the apoptotic pathway, i.e., there is no evidence
currently that the TGF- β s effect DNA synthesis arrest; however, this
possibility has not been completely ruled out. TGF- β s are made and
secreted by cells in a latent non-active form. To be effective as
tumor growth inhibitors, the latent TGF- β s must be activated by

induction of cell surface proteins that provide a proper structure for processing and activating proteases that cut the latent protein and release the active TGF- β .

The compounds of the present invention are shown to
5 activate proteases such as cathepsin D family proteases, and upregulate the mannose-6-phosphate receptor which binds inactive TGF- β and permits activation via proteases. Active TGF- β signals via cell membrane TGF- β receptors I and II to activate down stream kinases referred to as stress kinases or c-Jun N-terminal Kinases
10 (JNK) which phosphorylate and activate transcription factors c-Jun, ATF-2 and Elk-1. Prolonged activation of transcription factor c-Jun causes tumor cells to undergo apoptosis. These transcription factors, acting as homodimers or heterodimers with a multitude of transcription factor partners activate proapoptotic genes and/or
15 downregulate antiapoptotic genes leading to DNA fragmentation. The compounds of the present invention do not generate an anti-proliferative outcome to TGF- β signaling in normal non-tumor cells.

A second apoptotic inducing mechanism called the Fas/Fas ligand apoptotic signaling pathway is activated by the novel
20 compounds of the present invention. Activated Fas/Fas ligand signaling may lead to rapid cell death by apoptosis. Thus, for tumor cells to escape death by Fas/Fas ligand, they must inactivate this most important apoptotic pathway. The mechanism for inactivation of the Fas/Fas ligand signaling pathway by tumor cells varies;
25 however, many tumor cells down regulate the expression of Fas receptor and Fas ligand on their membranes.

Most important, R,R,R-2-(2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)chroman-6-yloxy)acetic acid (1) has been shown to induce Fas/Fas ligand resistant tumor cells to become Fas/Fas

ligand sensitive. Compound 1 also has the ability to enhance the expression of Fas ligand on the membrane of LNCaP prostate cells. Studies show that Fas signaling resistant human breast cancer cells retain the Fas receptor in their cytoplasm, but when cultured with
5 compound 1, the Fas receptor is transported from the cytoplasm to the membrane; thereby rendering the cells Fas signaling sensitive. Furthermore, this compound is synergistic in anti-Fas triggered apoptosis in that greater amounts of cell killing is obtained with both human breast and prostate cancer cells when co-treated versus
10 when treated separately. The ability of compound 1 to convert Fas signaling resistant tumor cells to Fas signaling sensitive tumor cells and to exhibit synergistic killing effects provides an extremely important mechanism for destruction of tumor cells both by the host immune surveillance system as well as by pharmaceutical
15 intervention. The compounds of the present invention do not activate the Fas signaling pathway of normal non-tumor cells.

These compounds activate the JNK kinase signaling pathway, perhaps by TGF- β and Fas/Fas ligand signaling. Prolonged activation of JNK results in prolonged activation of c-Jun and ATF-2
20 transcription factors, which are postulated to play a role in expression or repression of proapoptotic and antiapoptotic genes, respectively.

EXAMPLE 13

25

Mechanism of Induction of DNA Synthesis Arrest, Cell Cycle Arrest and Cellular Differentiation

The mechanisms of growth inhibition by DNA synthesis arrest, cell cycle arrest and by induction of cellular differentiation

have not been characterized as fully as the mechanism of growth inhibition by apoptosis. Studies show that the compounds of the present invention have profound effects on the cell cycle, inducing DNA synthesis arrest of approximately 95% of the tumor cells within 24 hours of treatment. Tumor cells cultured with the compounds disclosed herein are growth inhibited in the G1 cell cycle phase, undergo morphological changes and express milk lipids, an indication that the cell cycle blocked cells have undergone differentiation. P21, a gene known to be an inhibitor of entrance of cells from the G1 cell cycle phase to the S phase of the cell cycle, and the mRNA, as well as the protein of P21 gene, is up-regulated by treatment of MDA-MB-435 human breast cancer cells with compound 1.

15

EXAMPLE 14

In Vivo Potential for Human Cancer Cells

The present invention has potential for use as therapeutic agents. In vivo studies of tumor growth and metastasis of human tumor cells either ectopically or orthotopically transplanted into immune compromised animals, such as nude mice, or in vivo studies employing well recognized animal models are conducted. Inhibition of growth of human tumor cells transplanted into immune compromised mice provides pre-clinical data for clinical trials. In vivo studies include two human tumor cell models, the metastatic non-estrogen responsive MDA-MB-435 breast cancer model, and the androgen non-responsive PC-3 prostate cancer model.

MDA-MB-435 Breast Cancer Model:

Pathogen free MDA-MB-435 human breast cancer cells stably transfected with a marker protein (fluorescent green protein) are grown as a solid tumor in immune compromised nude or SCID mice. The tumors are removed, and 1 mm sections of equal size are orthotopically transplanted into the mammary fat pad or ectopically transplanted into the hind flank of female nude mice. Tumor growth, metastasis, and death of the animals are determined. Tumor growth is measured by caliper evaluations of tumor size. At the time of sacrifice, tumors are removed, measured for size, and used for histochemical examination. Organs such as spleen, lymph nodes, lungs, and bone marrow, are examined for metastatic MDA-MB-435 cells by histochemical staining of tissue sections for expression of the marker fluorescent green protein.

15

PC-3 Prostate Cancer Model

Pathogen free PC-3 human prostate cancer cells stably transfected with a marker protein (fluorescent green protein) are grown as a solid tumor in nude mice. The tumors are removed, and 1 mm sections of equal size are ectopically transplanted into the hind flank of male nude mice. Tumor growth, metastasis, and death of the animals are determined. At the time of sacrifice, tumors are removed, measured for size, and used for histochemical examination. Organs such as spleen, lymph nodes, lungs, bone marrow, are examined for metastatic PC-3 cells by histochemical staining of tissues for expression of the marker fluorescent green protein.

25

Skin Cancer Animal Model

Skin cancer is induced in SENCAR and SKH-1 hairless mice by ultraviolet irradiation and chemical (DMBA) treatments. In addition, mice specifically expressing the oncogene Her-2/neu in skin basal cells that spontaneously develop skin cancer are used. The compounds disclosed herein are topically applied to the skin daily, before and after skin cancer initiation, and development of skin papilloma formation is assessed. Control mice are treated identically except that they receive vehicle treatments topically applied to their skin. The efficacy of these compounds in treating papilloma's as well as their ability to affect malignant conversion when supplied prior to premalignant progression is monitored.

15

EXAMPLE 15Supplementation with Novel Compounds

Prior to initiation of the in vivo experiments, the compounds of this invention that exhibit the greatest amount of tumor cell killing are administered to nude, SCID, transgene, and other mice at varying levels to establish the highest level of compound that can be administered safely without adverse effects. The compounds are administered in a model-appropriate manner; e.g., orally, injections, including injections directly into the target organ, or topically. After establishing the highest level of the compounds that can be tolerated and effective administration routes, the novel compounds are administered to the mice on a daily basis, and tumor growth and progression is determined as described above.

EXAMPLE 16Establishing Maximum Tolerated Dose (MTD) of Compound 1

Prior to conducting the preclinical chemotherapeutic studies, compound 1 is assayed in non-tumor Balb/c female mice in an effort to establish the maximum tolerated dose. Compound 1 is dissolved in 100% ethanol to establish a stock solution (2 grams of compound 1 in 5 mls of 100% ethanol) and diluted in peanut oil (non vitamin E supplemented) to yield 20, 10, and 5 mg/0.1 ml. RRR- α -tocopherol succinate (VES; the succinate moiety is attached to RRR- α -tocopherol via an ester linkage) was solubilized and diluted as described above to yield 20 mg/0.1ml/gavage, serving as an additional control. A total of 30 Balb/c female mice were placed into 6 groups (5 mice/group) and supplemented by gavage with compound 1 daily for a total of 23 days. Group 1 mice were non treated and served as control; group 2 mice were the vehicle control group and received 0.1ml of vehicle (ethanol + peanut oil equivalent to treatment groups)/mouse/day for a total of 23 days, group 3 mice received 20 mg/ml of VES daily for a total of 23 days. Treatment groups 3, 4 and 5 were gavaged daily for 23 days with 5, 10, and 20 mgs of compound 1. Compound 1 at 5, 10, and 20 mg/day, administered daily by gavage to mice in groups 3, 4, and 5, respectively, for 23 days is tolerated well by the mice. Weights are determined weekly and there is no significant difference in the weights of the mice receiving compound 1 at 5, 10, and 20 mg/day when compared with the weights of the VES treated, untreated and vehicle treated control mice (Figure 8, data is for days 11 and 23 days treatment). Mice remained active and showed no signs of

toxicity. At the completion of the MTD studies, mice were sacrificed and no evidence of toxicity was observed upon autopsy.

5

EXAMPLE 17

Chemotherapeutic effectiveness of compound 1

The maximum tolerated dose studies show that compound 1 administered at the highest level (20 mg/day/23 days) is not toxic; however, due to the non-toxic levels used, an maximum tolerated dose was not established. For the preclinical chemotherapeutic studies, in the absence of an maximum tolerated dose, the mice are supplemented with 30 and 20 mgs/0.1ml by gavage daily for 21 days. Compound 1 is dissolved in 100% ethanol at 2 grams of compound 1/5mls of ethanol, and diluted in peanut oil (nonsupplemented vitamin E) to yield 30 and 20 mgs of compound 1 per 0.1ml. Vehicle control consisted of a mixture of ethanol and peanut oil equivalents. The preclinical chemotherapeutic studies are conducted with compound 1, utilizing human MDA-MB-435 human breast cancer cells, human DU-145 prostate cancer cells, and human HT-20 colon tumor cells transplanted into Balb/c immune compromised nude mice.

A total of 40 immune compromised nude mice are utilized for testing each test compound (two treatment groups at 20 and 30 mg/day) in each tumor cell type. Four experimental treatment groups of 10 mice each (vehicle/0.1ml/gavage daily for 21 days, compound 1 at 30 mgs of compound #1/0.1ml gavage/daily for 21 days, and compound 1 at 20 mgs/of compound 1/0.1ml gavage daily for 21 days, for each tumor type are used. An

established dosage of effective chemotherapeutic drugs are used in the xenograft studies. Taxol at 20/mg/kg, administered intraperitoneally daily for 5 days, is used for a positive control for human MDA-MB-435 breast cancer xenografts; Mitoxantrone at 1
5 mg/kg, administered daily intravenously for 5 days, is used as the positive control for human DU-145 prostate cancer cells; and 5 Fluorouracil (5 FU) at 30 mg/kg, administered daily for 5 days, is used for a positive control for human HT-29 colon cancer cells. Tumor cells are transplanted subcutaneously into the left flank and
10 permitted to grow to approximately 70 mg in size, test compound treatments by daily gavage are initiated, and continue for a total of 21 days. Mice are monitored daily for tumor size by caliper measurements. Mice are treated for 21 days; however, the mice are sacrificed when the tumors of the vehicle control reached 500
15 mg in weight. At the completion of the protocol, tumors are excised and tumor size established by weight. At the time of sacrifice, serum, tumor, and heart muscle are taken from animals in the two compound 1 test groups in order to establish levels of compound 1 via HPLC analyses (data not included). The
20 chemotherapeutic effectiveness of compound 1 administered daily at 30 and 20 mgs/day is determined by comparing the tumor size of the two treatment groups with the vehicle control group for each of the three tumor types, and by comparing the size of the tumor in the two treatment groups with the tumor group from the positive
25 control. Treatment is for 21 days, experiments are continued until mean weight of tumor for vehicle control reaches 500 mgs.

The *in vivo* preclinical chemotherapeutic data are depicted in Tables 3 and 4 and Figure 9A-C and are presented for 21-22 days of treatment. Treatment of nude mice transplanted with

human MDA-MB-435 breast cancer cells with compound 1 for 21 days at 20 and 30 mg/day by gavage reduced the mean tumor weight (mg) of the transplanted tumor cells by 20.7 and 44.6%, respectively when compared to the mean tumor weight of the vehicle control group at day 21 after treatment. The positive control, Taxol, reduces the mean tumor growth, when compared to mean tumor growth of vehicle control group, by 90.3% (Table 3, 4 & Figure 9A). Data are converted to percent mean tumor growth in relation to weight gain at the beginning of treatment (day 1) and are depicted in Table 4. Treatment of nude mice transplanted with human DU-145 prostate cancer cells with compound 1 for 21 days at 20 and 30 mg/day by gavage reduces the mean tumor weight (mg) of the transplanted tumor cells by 31.5 and 24.8%, respectively, when compared to the mean tumor weight of the vehicle control group at day 22 (Table 3, 4 & Figure 9B). The positive control, mitoxantrone reduces the mean tumor growth, when compared to mean tumor growth of vehicle control group, by 27.9%. Treatment of immune compromised nude mice transplanted with human HT-29 human colon cancer cells with compound 1 for 21 days at 20 and 30 mg/day by gavage reduces the mean tumor weight (mg) of the transplanted tumor cells by 33.3 and 34.5 %, respectively when compared to the mean tumor weight of the vehicle control group at day 22 (Table 3, 4 & Figure 9C). The positive control, 5 Fluorouracil, reduces the mean tumor growth, when compared to mean tumor growth of vehicle control group, by 31.4%.

TABLE 3

MDA-MB-435 Human Breast Cancer Cells Transplanted in to Nude Mice

		Mean tumor Weights (mg) Following Treatments						
5	Treatments	1	4	7	10	14	17	21
	Vehicle	70.1	98.2	119.5	153.2	172.8	203.7	226.1
	#1 (20 mg)	70.1	85.8	123.9	127.9	147.2	143.8	179.4
	#1 (30 mg)	68.1	85.7	97.3	98.4	126.6	118.7	125.2
	Taxol	70.7	71.5	38.2	11.7	5.7	3.6	6.8

10 DU-145 Human Prostate Cancer Cells Transplanted into Nude Mice

		Mean tumor Weights (mg) Following Treatments						
	Treatments	1	5	8	12	15	19	22
	Vehicle	66.5	111.4	167.1	258.5	351.1	458.3	540.9
	#1 (20 mg)	66.5	103.5	137.9	208	254.8	362.2	370.5
15	#1 (30 mg)	67.8	102.5	131.3	241.2	256.8	379.9	407
	Mitoxantrone	66.8	107.2	141.1	185.4	205.2	325.3	389.4

HT-29 Human Colon Cancer Cells Transplanted into Nude Mice

		Mean tumor Weights (mg) Following Treatments						
	Treatments	1	5	8	12	15	19	22
20	Vehicle	80.3	91.7	133.2	185.6	204.8	260.1	372.2
	#1 (20 mg)	59.5	84.0	97.0	124.6	147.3	198.0	248.2
	#1 (30 mg)	40.0	83.0	96.7	129.3	144.1	176.1	243.8
	5-FU	59.3	87.5	105.8	145.8	141.6	212.3	255.5

Table 4:

Percent mean tumor weight gain (mg) following treatments

MDA-MB-435 Human Breast Cancer Cells

Percent Mean tumor Weight Gain (mg) Following Treatments¹

5	Treatments	1	4	7	10	14	17	21
	Vehicle	100	140.1	170.5	218.5	246.5	290.6	322.5
	#1 (20 mg)	100	122.4	176.7	182.5	210.0	205.1	255.9
	#1 (30 mg)	100	125.8	142.9	144.5	185.9	174.3	178.6
	Taxol	100	101.1	-46.0	-83.7	-91.8	-99.5	-90.3
10	DU-145 Human Prostate Cancer Cells							
	Percent Mean tumor Weight Gain (mg) Following Treatments							
	Treatments	1	5	8	12	15	19	22
	Vehicle	100	167.5	251.3	388.7	528.0	458.3	689.2
	#1 (20 mg)	100	155.6	207.4	312.8	383.2	362.2	544.7
15	#1 (30 mg)	100	151.2	193.7	355.8	378.8	379.9	560.3
	Mitoxantrone	100	160.5	211.2	277.5	307.2	487.0	582.9
	HT-29 Human Colon Cancer Cells							
	Percent Mean tumor Weight Gain (mg) Following Treatments							
	Treatments	1	5	8	12	15	19	22
20	Vehicle	100	152.1	220.9	307.8	339.6	431.3	617.2
	#1 (20 mg)	100	141.2	163.0	209.4	247.6	332.8	417.1
	#1 (30 mg)	100	139.5	162.5	217.3	242.2	296.0	409.7
	5-FU	100	147.6	178.4	245.9	247.2	358.0	430.0

¹Percent Mean Tumor Weight Gain (mg) following treatment was determined by dividing the mean tumor weight at various time periods following treatment by the mean tumor weight at day 1 within the same treatment group and multiplying by 100.

EXAMPLE 18Preparation of Stock Solution, Vehicle and Compound 1 Dilutions

Compound 1 was prepared weekly, and stored at 4°C.

5 The preparation procedures are as follows:

Stock Solution of Compound 1:

Dissolve 2 grams of compound 1 in 5 mls of 100% ethanol (ETOH) and vortex at 37°C. This is the maximum amount of compound 1 that will go into solution.

10 For the following dilutions, dry compound 1 is added to yield the appropriate levels of compound 1 while keeping the ethanol levels equal in the two experimental groups and the vehicle control group.

Compound 1 at 30 mg/0.1ml gavage/mouse:

15 Combine 1 ml of compound 1 stock solution, 3 mls of vitamin E depleted peanut oil and 800 mg of compound #1 (dry) and vortex at 37°C.

Compound 1 at 20 mg/0.1ml gavage/mouse:

20 Combine 1 ml of compound 1 stock solution, 3 mls of vitamin E depleted peanut oil and 400 mg of compound #1 (dry) and vortex at 37°C approximate 2 h until in solution.

Compound 1 at 10 mg/0.1ml gavage/mouse:

Combine 1 ml of compound 1 stock solution and 3 mls of vitamin E depleted peanut oil.

25 Vehicle:

Combine 1 ml ETOH 3 mls of vitamin E depleted peanut oil.

EXAMPLE 19Chemopreventive properties of compound 1 in an ACI rat cancer model

5 Compound 1 is used in vivo to treat transplanted human breast, prostate, and colon tumors transplanted in immune compromised nude mice. The chemopreventive effectiveness of compound 1 in vivo against human breast cancer is shown in an estrogen cancer initiated ACI rat breast cancer model.

10 Approximately 90% of rats implanted with estrogen pellets develop breast cancer within 6 months after estrogen implantation.

 Compound 1 is dissolved in 100% ethanol and is diluted to the appropriate dosage using vitamin E depleted peanut oil. The maximum tolerated dose (MTD, maximum dose of compound that

15 can be administered without adverse affects) is determined as described in Examples 14 and 15. Compound 1 is administered at the maximum tolerated dose and 50% of the maximum tolerated dose. ACI rats at 4 weeks of age are subpannicularly implanted with estrogen pellets in the shoulder region. Compound 1 at maximum

20 tolerated dose and 50% of the maximum tolerated dose is administered by gavage. Breast tumors are detected in the control group at approximately 100 days following estrogen implantation. Ninety percent of the control rats develop breast cancer within 6 months after estrogen implantation. Tumor bearing animals from

25 control and treatment groups are sacrificed at various time intervals after treatment initiation, and mammary tissue is examined for obvious tumors, and further examined by histological analyses.

The following references are cited herein.

1. Colowisk, Sidney, P. and Kaplan, Nathan, O. *Methods in Enzymology*, Vol. XVIII, Vitamins and Coenzymes, Part C. Edited by Donald B. McCormick and Lemuel D. Wright. Section XII, 5 PP. 335.


2. Dhar, A., Liu, S., Klucik, J., Berlin, K.D., Madler, M.M., Lu, S., Ivey, R.T., Zacheis, D., Brwon, C.W., Nelson, E.C., Birchbichler, P.J., Benbrook, D.M. Synthesis, Structure-Activity Relationships, and RAR γ -Ligand Interactions of Nitrogen 10 Heteroarotinoids. *J. Med. Chem.* 42, pp. 3602-3614 (1999).

Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. Further, these patents and publications are incorporated by reference herein to the same 15 extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent 20 therein. The present examples along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those 25 skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.

WHAT IS CLAIMED IS:

1. A compound having a structural formula



- 5 wherein X is selected from the group consisting of oxygen, nitrogen and sulfur;

 Y is selected from the group consisting of oxygen, nitrogen and sulfur wherein when Y is oxygen or nitrogen, n is 1 and when Y is sulfur, n is 0;

- 10 R¹ is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxylic acid, carboxylate, carboxamide, ester, thioamide, thiolacid, thiolester, saccharide, alkoxy-linked saccharide, amine, sulfonate, sulfate, phosphate, alcohol, ethers and nitriles;

- 15 R² is selected from the group consisting of hydrogen, methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylolester, saccharide and amine;

- R³ is selected from the group consisting of hydrogen, methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylolester, saccharide and amino;
- 20 R⁴ is selected from the group consisting of methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylolester, saccharide and amine; and

- R⁵ is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxyl, amide and ester;
- 25


wherein when Y is nitrogen, said nitrogen is substituted with R^6 , wherein R^6 is selected from the group consisting of hydrogen and methyl;

wherein when X is oxygen and Y is oxygen, R^2 is methyl,
 5 R^3 is methyl, R^4 is methyl and R^5 is phytyl, R^1 is not butyric acid.

2. The compound of claim 1, wherein said compound is selected from the group consisting of 2,5,7,8-tetramethyl-(2R-
 10 (4R,8R,12-trimethyltridecyl)chroman-6-yloxy)acetic acid, 2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy) propionic acid, 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyl
 tridecyl)chroman-6-yloxy) valeric acid, 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy) hexanoic acid,
 15 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyl tridecyl)chroman-6-yloxy) octanoic acid, 2,5,8-trimethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy)acetic acid, 2,7,8-trimethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy) acetic acid, 2,8-dimethyl-(2R-(4R,8R,12-trimethyltridecyl) chroman-6-yloxy) acetic
 20 acid, 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy) acetamide, methy 12,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl) chroman-6-yloxy) acetate, 2-(N,N-(carboxymethyl)-2(2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyl
 tridecyl) chroman-6-yloxy) acetic acid, 2-(2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy))ethan-1-ol, 2-
 25 (2,5,7,8-pentamethylchroman-6-yloxy)acetic acid, 2,5,7,8-tetramethyl-(2RS-(4RS,8RS,12-trimethyltridecyl)chroman-6-yloxy) acetic acid, 2,5,7,8-tetramethyl-(2R-(carboxy)chroman-6-yloxy))acetic acid, 2,5,7,8-tetramethyl-2R-(2RS,6RS,10-

trimethylundecyl)chroman-6-yloxy)acetic acid, 2,5,7,8,-
 tetramethyl-2R-(2,6,10-trimethyl-1,3,5,9 E:Z decatetraen)chroman-
 6-yloxy)acetic acid, 3-(2,5,7,8-tetramethyl-(2R-(4R,8,12-
 trimethyltridecyl)chroman-6-yloxy)propyl-1-ammonium chloride,
 5 2,5,7,8-tetramethyl-(2R-(4r,8R,12-trimethyltridecyl)chroman-3-ene
 -6-yloxy) acetic acid, 6-(2,5,7,8-tetramethyl-(2R-(4R,8,12-
 trimethyltridecyl)chroman)acetic acid, 2,5,7,8,-tetramethyl-(2R-
 (heptadecyl)chroman-6-yloxy) acetic acid 2,5,7,8-tetramethyl-(2R-
 (heptyl)chroman-6-yloxy)acetic acid, 2,5,7,8,-tetramethyl-(2R-
 10 (tridecyl)chroman-6-yloxy) acetic acid, 2,5,7,8,-tetramethyl-(2R-
 (heptadecyl)chroman-6-yloxy) acetic acid, 2,5,7,8,-tetramethyl-2R-
 (4,8,-dimethyl-1,3,7 E:Z nonotrien)chroman-6-yloxy) acetic acid,
 E,Z,RS,RS-(phytyltrimethylbenzenethiol-6-yloxy)acetic acid, (R)-
 2((2,5,7,8-tetramethyl-2-(3 propene methyl ester)chroman-6-
 15 yloxy)acetic acid, 2,5,7,8-tetramethyl-(2R-(propionate)chroman-6-
 yloxy)acetic acid, 1-aza- α -tocopherol-6-yloxyl-acetic acid, 1-aza- α -
 tocopherol-6-yloxyl-methyl acetate, 1-aza-N-methyl- α -tocopherol-6-
 yloxyl-methyl acetate, 1-aza-N-methyl- α -tocopherol-6-yloxyl-acetic
 acid, and 6-(2,4-Dinitrophenylazo(2,5,7,8-tetramethyl-2-(4,8,12-
 20 trimethyltridecyl)-1,2,3,4-tetrahydroquinoline.

3. A method for the treatment of a cell proliferative
 disease comprising administering to an animal a pharmacologically
 25 effective dose of a compound having a structural formula



wherein X is selected from the group consisting of oxygen, nitrogen and sulfur;

Y is selected from the group consisting of oxygen, nitrogen and sulfur wherein when Y is oxygen or nitrogen, n is 1 and
5 when Y is sulfur, n is 0;

R¹ is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxylic acid, carboxylate, carboxamide, ester, thioamide, thiolacid, thiolester, saccharide, alkoxy-linked
10 saccharide, amine, sulfonate, sulfate, phosphate, alcohol, ethers and nitriles;

R² is selected from the group consisting of hydrogen, methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide and amine;

R³ is selected from the group consisting of hydrogen, methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl
15 carboxamide, benzylester, saccharide and amine;

R⁴ is selected from the group consisting of methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide and amine; and

20 R⁵ is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxyl, amide and ester;

wherein when Y is nitrogen, said nitrogen is substituted with R⁶, wherein R⁶ is selected from the group consisting of hydrogen and methyl.

25

4 The method of claim 3, wherein said compound is selected from the group consisting of 2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy)acetic acid, 2,5,7,8-

tetramethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy)
 propionic acid, 2,5,7,8-tetramethyl-(2R-(4R,8R,12-
 trimethyltridecyl) chroman-6-yloxy)butyric acid, 2,5,8-trimethyl-
 (2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy)acetic acid, 2,7,8-
 5 trimethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy) acetic
 acid, 2,8-dimethyl-(2R-(4R,8R,12-trimethyltridecyl) chroman-6-
 yloxy) acetic acid, 2-(N,N-(carboxymethyl)-2(2,5,7,8-tetramethyl-
 (2R-(4R,8R,12-trimethyltridecyl) chroman-6-yloxy) acetic acid,
 2,5,7,8-tetramethyl-(2RS-(4RS,8RS,12-trimethyl tridecyl)chroman-
 10 6-yloxy)acetic acid, 2,5,7,8-tetramethyl-2R-(2RS,6RS,10-
 trimethylundecyl)chroman-6-yloxy)acetic acid, 3-(2,5,7,8-
 tetramethyl-(2R-(4R,8,12-trimethyltridecyl)chroman-6-
 yloxy)propyl-1-ammonium chloride, 2,5,7,8-tetramethyl-(2R-
 (4r,8R,12-trimethyltridecyl)chroman-3-ene-6-yloxy) acetic acid, 2-
 15 (2,5,7,8-tetramethyl-(2R-(4R,8,12-trimethyltridecyl) chroman-6-
 yloxy)triethylammonium sulfate, 6-(2,5,7,8-tetramethyl-(2R-
 (4R,8,12-trimethyltridecyl)chroman)acetic acid, 2,5,7,8,-
 tetramethyl-(2R-(heptadecyl)chroman-6-yloxy) acetic acid, 2,5,7,8,-
 tetramethyl-2R-(4,8,-dimethyl-1,3,7 E:Z nonotrien)chroman-6-
 20 yloxy) acetic acid, E,Z,RS,RS-(phytyltrimethylbenzenethiol-6-
 yloxy)acetic acid, 1-aza- α -tocopherol-6-yloxyl-acetic acid, and 1-
 aza-N-methyl- α -tocopherol-6-yloxyl- acetic acid.

25 5. The method of claim 3, wherein said compound
 exhibits an anti-proliferative effect comprising apoptosis, DNA
 synthesis arrest, cell cycle arrest, or cellular differentiation.

6. The method of claim 3, wherein said animal is a human.

5 7. The method of claim 3, wherein said composition is administered in a dose of from about 1 mg/kg to about 60 mg/kg.

8. The method of claim 3, wherein administration of
10 said composition is selected from the group consisting of oral, topical, intraocular, intranasal, parenteral, intravenous, intramuscular, or subcutaneous.

15 9. The method of claim 3, wherein said cell proliferative disease is selected from the group consisting of neoplastic diseases and non-neoplastic disorders.

20 10. The method of claim 9, wherein said neoplastic disease is selected from the group consisting of ovarian cancer, cervical cancer, endometrial cancer, bladder cancer, lung cancer, breast cancer, testicular cancer, prostate cancer, gliomas, fibrosarcomas, retinoblastomas, melanomas, soft tissue sarcomas,
25 osteosarcomas, leukemias, colon cancer, carcinoma of the kidney, pancreatic cancer, basal cell carcinoma, and squamous cell carcinoma.

11. The method of claim 9, wherein said non-neoplastic disease is selected from the group consisting of psoriasis, benign proliferative skin diseases, ichthyosis, papilloma, restinosis, scleroderma, hemangioma, viral diseases, and autoimmune diseases.

5

12. The method of claim 11, wherein said autoimmune diseases are selected from the group consisting of autoimmune thyroiditis, multiple sclerosis, myasthenia gravis, systemic lupus erythematosus, dermatitis herpetiformis, celiac disease, and rheumatoid arthritis.

13. The method of claim 9, wherein said non-neoplastic disorders are selected from the group consisting of viral disorders and autoimmune disorders.

14. The method of claim 13, wherein said viral disorder is Human Immunodeficiency Virus.


15. The method of claim 13, wherein said autoimmune disorders are selected from the group consisting of the inflammatory process involved in cardiovascular plaque formation, ultraviolet radiation induced skin damage and disorders involving an immune component.

16. A pharmaceutical composition, comprising the compound of claim 3 and a pharmaceutically acceptable carrier.

5 17. The pharmaceutical composition of claim 16, wherein said compound is selected from the group consisting of 2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy)acetic acid, 2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy)propionic acid, 2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy)butyric acid, 2,5,8-trimethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy)acetic acid, 2,7,8-trimethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy)acetic acid, 2,8-dimethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy)acetic acid, 2-(N,N-(carboxymethyl)-2(2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy)acetic acid, 2,5,7,8-tetramethyl-(2RS-(4RS,8RS,12-trimethyltridecyl)chroman-6-yloxy)acetic acid, 2,5,7,8-tetramethyl-2R-(2RS,6RS,10-trimethylundecyl)chroman-6-yloxy)acetic acid, 3-(2,5,7,8-tetramethyl-(2R-(4R,8,12-trimethyltridecyl)chroman-6-yloxy)propyl-1-ammonium chloride, 2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-3-ene-6-yloxy)acetic acid, 2-(2,5,7,8-tetramethyl-(2R-(4R,8,12-trimethyltridecyl)chroman-6-yloxy)triethylammonium sulfate, 6-(2,5,7,8-tetramethyl-(2R-(4R,8,12-trimethyltridecyl)chroman)acetic acid, 2,5,7,8-tetramethyl-(2R-(heptadecyl)chroman-6-yloxy)acetic acid, 2,5,7,8-tetramethyl-2R-(4,8,-dimethyl-1,3,7 E:Z nonotrien)chroman-6-yloxy)acetic acid, E,Z,RS,RS-(phytyltrimethylbenzenethiol-6-

ylxy)acetic acid, 1-aza- α -tocopherol-6-yloxy-acetic acid, and 1-aza-N-methyl- α -tocopherol-6-yloxy-acetic acid.

- 5 18. A method of inducing apoptosis of a cell, comprising the step of contacting said cell with a pharmacologically effective dose of a compound having a structural formula



- 10 wherein X is selected from the group consisting of oxygen, nitrogen and sulfur;

Y is selected from the group consisting of oxygen, nitrogen and sulfur wherein when Y is oxygen or nitrogen, n is 1 and when Y is sulfur, n is 0;

- 15 R¹ is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxylic acid, carboxylate, carboxamide, ester, thioamide, thiolacid, thiolester, saccharide, alkoxy-linked saccharide, amine, sulfonate, sulfate, phosphate, alcohol, ethers and nitriles;

- 20 R² is selected from the group consisting of hydrogen, methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide and amine;

- 25 R³ is selected from the group consisting of hydrogen, methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide and amine;

R⁴ is selected from the group consisting of methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide and amine; and

R⁵ is selected from the group consisting of alkyl, alkenyl,
5 alkynyl, aryl, heteroaryl, carboxyl, amide and ester;

wherein when Y is nitrogen, said nitrogen is substituted with R⁶, wherein R⁶ is selected from the group consisting of hydrogen and methyl.

10

19. The method of claim 18, wherein said compound is selected from the group consisting of 2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy)acetic acid, 2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy)
15 propionic acid, 2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl) chroman-6-yloxy)butyric acid, 2,5,8-trimethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy)acetic acid, 2,7,8-trimethyl-(2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy) acetic acid, 2,8-dimethyl-(2R-(4R,8R,12-trimethyltridecyl) chroman-6-yloxy) acetic acid, 2-(N,N-(carboxymethyl)-2(2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl) chroman-6-yloxy) acetic acid, 2,5,7,8-tetramethyl-(2RS (4RS,8RS,12-trimethyltridecyl)chroman-6-yloxy)acetic acid, 2,5,7,8-tetramethyl-2R-(2RS,6RS,10-trimethylundecyl)chroman-6-yloxy)acetic acid, 3-(2,5,7,8-tetramethyl-(2R-(4R,8,12-trimethyltridecyl)chroman-6-yloxy)propyl-1-ammonium chloride, 2,5,7,8-tetramethyl-(2R-(4r,8R,12-trimethyltridecyl)chroman-3-ene-6-yloxy) acetic acid, 2-(2,5,7,8-tetramethyl-(2R-(4R,8,12-trimethyltridecyl) chroman-6-yloxy)triethylammonium sulfate, 6-(2,5,7,8-tetramethyl-(2R-

25

(4R,8,12-trimethyltridecyl)chroman)acetic acid, 2,5,7,8,-
tetramethyl-(2R-(heptadecyl)chroman-6-yloxy) acetic acid, 2,5,7,8,-
tetramethyl-2R-(4,8,-dimethyl-1,3,7 E:Z nonotrien)chroman-6-
yloxy) acetic acid, E,Z,RS,RS-(phytyltrimethylbenzenethiol-6-
5 yloxy)acetic acid, 1-aza- α -tocopherol-6-yloxyl-acetic acid, and 1-
aza-N-methyl- α -tocopherol-6-yloxyl- acetic acid.

20. The method of claim 18, wherein said method is
10 useful in the treatment of a cell proliferative disease.





FIG. 1

Compound	R ¹	R ²	R ³
Alpha (α)	CH ₃	CH ₃	CH ₃
Beta (β)	CH ₃	H	CH ₃
Gamma (γ)	H	CH ₃	CH ₃
Delta (δ)	H	H	CH ₃




Compound	R ¹	R ²	R ³	R ⁴	R ⁵
1	CH ₂ CO ₂ H	CH ₃	CH ₃	CH ₃	phytyl
2	(CH ₂) ₂ CO ₂ H	CH ₃	CH ₃	CH ₃	phytyl
3	(CH ₂) ₃ CO ₂ H	CH ₃	CH ₃	CH ₃	phytyl
4	(CH ₂) ₄ CO ₂ H	CH ₃	CH ₃	CH ₃	phytyl
5	(CH ₂) ₅ CO ₂ H	CH ₃	CH ₃	CH ₃	phytyl
6	(CH ₂) ₇ CO ₂ H	CH ₃	CH ₃	CH ₃	phytyl
7	CH ₂ CO ₂ H	CH ₃	H	CH ₃	phytyl
8	CH ₂ CO ₂ H	CH ₃	H	CH ₃	phytyl
9	CH ₂ CO ₂ H	H	H	CH ₃	phytyl
10	CH ₂ CONH ₂	CH ₃	CH ₃	CH ₃	phytyl
11	CH ₂ CO ₂ CH ₃	CH ₃	CH ₃	CH ₃	phytyl
12	CH ₂ CON(CH ₂ CO ₂ H) ₂	CH ₃	CH ₃	CH ₃	phytyl
13	CH ₂ CH ₂ OH	CH ₃	CH ₃	CH ₃	phytyl
14	CH ₂ CO ₂ H	CH ₃	CH ₃	CH ₃	CH ₃
15	RS CH ₂ CO ₂ H	CH ₃	CH ₃	CH ₃	phytyl

FIG. 2-1


Compound	R ¹	R ²	R ³	R ⁴	R ⁵
16	CH ₂ CO ₂ H	CH ₃	CH ₃	CH ₃	COOH
17	R/RS CH ₂ CO ₂ H	CH ₃	CH ₃	CH ₃	phytyl
18	CH ₂ CO ₂ H	CH ₃	CH ₃	CH ₃	isoprenyl
19	NH ₃ Cl	CH ₃	CH ₃	CH ₃	phytyl
20	CH ₂ CO ₂ H	CH ₃	CH ₃	CH ₃	phytyl
21	OSO ₃ NHEt ₃	CH ₃	CH ₃	CH ₃	phytyl
22	CH ₂ CO ₂ H	CH ₃	CH ₃	CH ₃	phytyl
23	CH ₂ CO ₂ H	CH ₃	CH ₃	CH ₃	phytyl
24	CH ₂ CO ₂ H	CH ₃	CH ₃	CH ₃	phytyl
25	CH ₂ CO ₂ H	CH ₃	CH ₃	CH ₃	phytyl
26	CH ₂ CO ₂ H	CH ₃	CH ₃	CH ₃	other
27	CH ₂ CO ₂ H	CH ₃	CH ₃	CH ₃	other
28	CH ₂ CO ₂ H	CH ₃	CH ₃	CH ₃	ester
29	CH ₂ CO ₂ H	CH ₃	CH ₃	CH ₃	ester



FIG. 2-2



$B^1 = \text{alkyl, alkenyl, alkynyl, aryl, and heteroaryl.}$



$B^1 = \text{alkyl, alkenyl, alkynyl, aryl, and heteroaryl carboxylic acids or carboxylates.}$




FIG. 3A-1




FIG. 3A-2





FIG. 3B-1

$R^1 = \text{alkyl, alkenyl, alkynyl, aryl, and heteroaryl amines.}$



$R^1 = \text{alkyl, alkenyl, alkynyl, aryl, and heteroaryl carboxamides.}$




FIG. 3B-2





FIG. 3C-1

B¹ = alkyl, alkenyl, aryl, and heteroaryl phosphates.



B¹ = alkyl, alkenyl, aryl, and heteroaryl alcohols, ethers, and nitriles.




FIG. 3C-2




FIG. 4-1





FIG. 4-2

R^3, R^4 = benzyl carboxylic acid or carboxylate.



R^3, R^4 = benzyl carboxamides or esters.




FIG. 5-1






FIG. 5-2


$R^5 =$ alkyl, alkenyl, alkynyl, aryl, and heteroaryl.



1) MeOH
 2) DiBAL-H
 3) PPh_3 , $n-BuLi$
 various alkyl-, alkenyl-,
 alkynyl-, aryl- and
 heteroaryl halides



$R^5 =$ alkyl, alkenyl, alkynyl, aryl, and heteroaryl amides and esters.



1) DCC, HOSu
 2) various alkyl-, alkenyl-,
 alkynyl-, aryl- and
 heteroaryl amines or alcohols




FIG. 6




FIG. 7A








FIG. 7B



Mean body weights of mice +/- S.D. with an n=5
ut = untreated; veh = vehicle control; VES-20 = ester succinated vitamin E at 20 mg/day; #1 = compound #1 at 20, 10, and 5 mg/day.

FIG. 8

MDA MB-435 Human Breast Cancer Cells




FIG. 9A

DU-145 Human Prostrate Cancer Cells




FIG. 9B

HT-29 Human Colon Cancer Cells




FIG. 9C

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/04163

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07D 311/20; C07H 17/06; A07K 31/355, 31/7028

US CL : 549/408, 410, 412; 536/4.1; 514/32, 456, 458

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 549/408, 410, 412; 536/4.1; 514/32, 456, 458

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN structure search, EAST, Caplus text search

search terms: tocopher?, chroman?, cancer, apoptosis, autoimmune, viral, HIV

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,114,957 A (HENDLER et al) 19 May 1992, see entire reference	3, 6-9, 11, 13, 14
X	US 5,315,017 A (LE BAUT et al) 24 May 1994, see entire reference	1-13, 15, 16
X	US 5,545,660 A (GRISAR et al) 13 August 1996, see entire reference	1, 3, 5-9, 11-13, 15, 16
X	US 4,457,918 A (HOLICK et al) 3 Jul 1984, see entire reference	1, 16
Y	US 5,135,945 A (ROBINSON et al) 4 Aug 1992, see entire reference	1-10, 16-20



Further documents are listed in the continuation of Box C.



See patent family annex.

A	document defining the general state of the art which is not considered to be of particular relevance	*I*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
B	earlier document published on or after the international filing date	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L	document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O	document referring to an oral disclosure, use, exhibition or other means	*Z*	document member of the same patent family
P	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

20 APRIL 2001

Date of mailing of the international search report

23 MAY 2001

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

LEIGH C. MAIER

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/04168

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	US 5,917,060 A (ROSENAU et al) 29 Jun 1999, see entire reference	1, 16 --- 2, 17
X --- Y	US 4,665,204 A (WIRTH) 12 May 1987, see entire reference	1, 1--2, 17
Y	FARISS, M. W. et al "The selective antiproliferative effects of alpha-tocopheryl hemisuccinate. . ." Cancer Res. Vol. 54, Pages 3346-3351, see entire reference	1-10, 16-20
X --- Y	DJURIC, Z. et al "Growth inhibition of MCF-7 and MCF10A human breast cells. . ." Cancer Lett., Vol. 111, pages 133-139, (Caplus abstract) see abstract.	1, 3, 5, 6, 8-10, 16 --- 2, 4, 7, 17-20